WO1992007844A1 - Quinazolines derivatives for enhancing antitumor activity - Google Patents

Quinazolines derivatives for enhancing antitumor activity Download PDF

Info

Publication number
WO1992007844A1
WO1992007844A1 PCT/US1991/007254 US9107254W WO9207844A1 WO 1992007844 A1 WO1992007844 A1 WO 1992007844A1 US 9107254 W US9107254 W US 9107254W WO 9207844 A1 WO9207844 A1 WO 9207844A1
Authority
WO
WIPO (PCT)
Prior art keywords
carbon atoms
methoxy
hydrogen
alkoxy
formula
Prior art date
Application number
PCT/US1991/007254
Other languages
French (fr)
Inventor
Jotham Wadsworth Coe
Anton Franz Fliri
Takushi Kaneko
Eric Robert Larson
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SK4009-92A priority Critical patent/SK400992A3/en
Priority to CS924009A priority patent/CZ400992A3/en
Priority to DE69111077T priority patent/DE69111077T2/en
Priority to US08/050,047 priority patent/US5444062A/en
Priority to KR1019930701349A priority patent/KR930702292A/en
Priority to EP92900750A priority patent/EP0556310B1/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Priority to JP92501815A priority patent/JPH05507290A/en
Priority to BR9107070A priority patent/BR9107070A/en
Publication of WO1992007844A1 publication Critical patent/WO1992007844A1/en
Priority to FI932032A priority patent/FI932032A0/en
Priority to NO931635A priority patent/NO931635D0/en
Priority to GR950402241T priority patent/GR3017122T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Definitions

  • This invention relates to 2,4-diaminoquinazolines and their use as sensitizers of tumor cells to anticancer agents.
  • MOR multidrug resistance
  • the drugs which are the target of resistance include adriaraycin, daunomycin, vinblastine, vincristine, actinomycin D and etoposide.
  • the resistance cells are often associated with over- expression of the mdrl gene.
  • This gene product is a family of 140-220 kd trans-membrane phosphoglycoprotein (P-glycoprotein) which functions as an ATP-dependent efflux pump.
  • P-glycoprotein trans-membrane phosphoglycoprotein
  • the 2,4-diaminoquinazolines are prepared by known methods utilizing 2,4-dichloroguinazolines [Postovskii and Goncharova, Zh. Obshch. Khim., 32, 3323 (1962)]. Curd et al. (J. Chem. Soc, 1947, 775) reported the synthesis of 2,4-dichloroquinazolines from the
  • Lacefield US patent 3,956,495 (1976)] describes compounds of the general formula I as antithrombotic agents. Crenshaw
  • the compound of the present invention are of the formula
  • Q is hydrogen, alkoxy of one to three carbon atoms, hydroxy, alkanoylamino having two to four carbon atoms, alkyl of one to three carbon atoms, bromo, iodo, chloro, fluoro, nitro, morpholino, amino, alkylamino of one to three carbon atoms or dialkylamino of two to six carbon atoms
  • Q 1 is hydrogen, fluoro, chloro, bromo, alkyl having one to three carbon atoms or alkoxy having one to three carbon atoms
  • Q 2 is hydrogen or alkoxy of one to three carbon atoms
  • Q 1 and Q 2 together are methylenedioxy or ethylenedioxy
  • R is hydrogen, alkyl having one to four carbon atoms or alkoxy of one to three carbon atoms
  • m is an integer of 0-2
  • p is an integer of 1-2
  • R 5 is hydrogen or dialkoxybenzyl said alkoxy having one to three carbon atom
  • R 6 is pyridylmethoxy, alkoxyalkyleneoxy said alkoxy having one to three carbon atoms and said alkylene having two to three carbon atoms or benzoxazol-2-ylmethyl
  • n is an integer of 1 or 0, W is O, S or a chemical bond, A is alkylene of one to four carbon atoms, Y is hydrogen, alkyl of one to three carbon atoms, fluoro, chloro, bromo, hydroxy, alkoxy of one to three carbon atoms, benzyloxy, nitro, dimethylamino or amino, Y 1 is hydrogen, alkoxy of one to three carbon atoms, chloro, fluoro, hydroxy or benzyloxy, Y 2 is hydrogen or alkoxy of one to three carbon atoms and Y and Y 1 together are methylenedioxy or ethylenedioxy,
  • R 7 is hydroxy, alkoxy of one to three carbon atoms or C 6 H 5 (CH 2 ) t 0, n is 1, t is an integer of 1 or 0,
  • A is alkylene of one to four carbon atoms, Q 3 and Q 4 are each hydrogen or alkoxy of one to three carbon atoms and Q 3 and Q 4 together are methylenedioxy or ethylenedioxy,
  • alkoxyalkyl said alkoxy having one to three carbon atoms and said alkyl having two to three carbon atoms
  • A is alkylene of one to four carbon atoms
  • Q 3 and Q 4 are each hydrogen or alkoxy of one to three carbon atoms and Q 3 and Q 4 together are ethylenedioxy or methylenedioxy
  • A is alkylene of one to four carbon atoms
  • Q 3 and Q 4 are each hydrogen or alkoxy of one to three carbon atoms and Q 3 and Q 4 together are ethylenedioxy or methylenedioxy;
  • W is O, S or a chemical bond and Q 3 is hydrogen or alkoxy of one to three carbon atoms,
  • A is alkylene having one to four carbon atoms
  • Q 3 and Q 4 are each hydrogen or alkoxy having one to three carbon atoms and Q 3 and Q 4 together are ethylenedioxy or methylenedioxy
  • Q 3 and Q 4 are each hydrogen or alkoxy of one to three carbon atoms and Q 3 and Q 4 together are ethylenedioxy or methylenedioxy,
  • R 4 is hydrogen or alkyl of one to eight carbon atoms and R 3 and R 4 taken together with the nitrogen atom to which they are attached form
  • Q 3 and Q 4 are each hydrogen or alkoxy of one to three carbon atoms and Q 3 and Q 4 together are methylenedioxy or ethylenedioxy,
  • R 8 is benzyl, alkoxyalkyleneoxy said alkoxy having from one to three carbon atoms and said alkylene having two to three carbon atoms or alkyl sulfonamide of the formula
  • R 9 is alkyl of one to four carbon atoms
  • R 10 is hydrogen, alkoxycarbonyl of two to six carbon atoms, acyl of one to six carbon atoms, hydroxyalkoxy- carbonyl of three to six carbon atoms, furoyl, benzoxazol-2- yl, pyrimid-2-yl or benzodioxan-2-ylcarbonyl.
  • a preferred group of compounds are those where X and X 1 are each alkoxy of one to four carbon atoms, X 2 is hydrogen, R 1 and R 2 when taken together with the nitrogen atom to which they are attached form a moiety of the formula
  • Y 1 and Y 2 are each methoxy, n is 0 , W is a chemical bond, A is ethylene and R 4 is hydrogen.
  • X is 6 -methoxy, X 1 is 7-methoxy, Q is 5-hydroxy, Q 1 is 6-methoxy, Q 2 is hydrogen, Y is hydrogen, Y 1 is 2-methoxy and Y 2 is 3 -methoxy, where X is 6-methoxy, X 1 is 7-methoxy, Q is 6-methoxy, Q 1 is 7 -methoxy, Q 2 is hydrogen, Y is hydrogen, Y 1 is 3-methoxy and Y 2 is 4 -methoxy, where X is 6-methoxy, X 1 is 7-methoxy, Q is 7-methoxy, Q 1 is 8-methoxy, Q 2 is hydrogen, Y is hydrogen, Y 1 is 2 -methoxy and Y 2 is 3-methoxy, where X is 6-methoxy, X 1 is 7-methoxy, Q
  • a second group of preferred compounds are those where X 1 and X 2 are each hydrogen, R 1 and R 2 when taken together with the nitrogen atom to which they are attached form a moiety of the formula
  • Q and Q 1 are each alkoxy of one to three carbon atoms
  • Q 2 is hydrogen
  • R and R 5 are each hydrogen
  • p is 1
  • m is 1
  • R 3 is aralkyl of the formula
  • Y 2 is hydrogen, n is 0, W is a chemical bond and A is ethylene and R 4 is hydrogen.
  • Especially preferred within this group are compound where X is 5-methoxy, Q is 6-methoxy, Q 1 is 7-methoxy, Y is 2-chloro and Y 1 is hydrogen, where X is 5-chloro, Q is 6-methoxy, Q 1 is 7-methoxy, Y is 2-chloro and Y 1 is hydrogen, where X is 5-methyl, Q is 6-methoxy, Q 1 is 7-methoxy, Y is 3-methoxy and Y 1 is 4-methoxy and where X is 6-dimethylamino, Q is 6-methoxy, Q 1 is 7-methoxy, Y is 3-methoxy and Y 1 is 4-methoxy.
  • a third group of preferred compounds are those where X and X 1 are each alkoxy of one to four carbon atoms, X 2 is hydrogen, R 1 and R 2 when taken together with the nitrogen atom to which they are attached form a moiety of the formula
  • Y and Y 1 are each alkoxy of one to three carbon atoms, Y 2 is hydrogen, n is 0, W is a chemical bond, A is ethylene and R 4 is hydrogen.
  • Especially preferred within this group are compounds where X is 6-methoxy, X 1 is 7-methoxy, Q and Q 1 are each hydrogen, p is 1, R is methoxy, m is 0, Y is 2-methoxy and Y 1 is 3-methoxy, where X is 6-methoxy, X 1 is 7-methoxy, Q and Q 1 are each hydrogen, p is 2, R is hydrogen, m is 1, Y is 3-methoxy and Y 1 is 4-methoxy and where X is 6-methoxy, X 1 is 7-methoxy, Q is 7-amino, Q 1 is hydrogen, R is hydrogen, m is 0, p is 1, Y is 3-methoxy and Y 1 is 4-methoxy.
  • a fourth group of preferred compounds those where X and X 1 are each alkoxy of one to four carbon atoms, R 1 and R 2 when taken together with the nitrogen atom to which they are attached form a moiety of the formula
  • Q and Q 1 are each alkoxy of one to three carbon atoms
  • Q 2 is hydrogen
  • R and R 5 are each hydrogen
  • p is 1
  • m is 1
  • R 3 is aralkyl of the formula
  • Q 3 and Q 4 are each alkoxy of one to three carbon atoms, R 7 is methoxy, n is 1, A is methylene and R 4 is hydrogen.
  • X is 6-methoxy
  • X 1 is 7-methoxy
  • Q is 6-fluoro
  • R is methoxy
  • Q 3 is 2-methoxy and Q 4 is 3-methoxy.
  • a fifth group of preferred compounds are those where X 1 is alkoxy of one to four carbon atoms, X 2 is hydrogen, R 1 and R 2 when taken together with the nitrogen atom to which they are attached form a moiety of the formula
  • Y 2 is hydrogen, n is 0, W is a chemical bond, A is ethylene and R, is hydrogen.
  • X is 6-chloro, X 1 is 7-methoxy, Q is 6-methoxy, Q 1 is 7-methoxy, R and R 5 are each hydrogen, Y is 3-methoxy and Y 1 is 4-methoxy.
  • the present invention also includes a method of inhibiting a P-glycoprotein in a mammal in need of such treatment which comprises administering to said mammal a P-glycoprotein inhibiting amount of a compound of formula I.
  • a method of inhibiting a P-glycoprotein in a mammal in need of such treatment which comprises administering to said mammal a P-glycoprotein inhibiting amount of a compound of formula I.
  • the method where the mammal is a human suffering from cancer and said compound is administered before, with or after the administration to said human of an anticancer effective amount of a chemotherapeutic agent.
  • a pharmaceutical composition for administration to a mammal which comprises a P-glycoprotein inhibiting amount of a compound of formula I, a pharmaceutically acceptable carrier and, optionally, an anticancer effective amount of a chemotherapeutic agent.
  • the compounds of formula I form pharmaceutically acceptable acid addition salts.
  • Said pharmaceutically acceptable acid addition salts include, but are not limited to, those with HCl, HBr, HNO 3 , H 2 SO 4 , H 3 PO 4 , CH 3 SO 3 H, p-CH 3 C 6 H 4 SO 3 H, CH 3 CO 2 H, gluconic acid, tartaric acid, maleic acid and succinic acid.
  • diacid addition salts e.g., the dihydrochloride
  • alkyl and “alkylene” are meant to embrace both straight chained and branched members.
  • 2,4-dichloroquinazoline and one molar equivalent of a tertiary amine-acid scavenger, such as triethylamine, N-methylmorpholine or diethylisopropylamine and one molar equivalent of an amine, R 1 R 2 NH, are combined in an anhydrous solvent such as dimethylacetamide, dioxane or N-methyl-2-pyrrolidone and maintained at from 0°C to about 25°C for a period of 1 to 48 hours.
  • an anhydrous solvent such as dimethylacetamide, dioxane or N-methyl-2-pyrrolidone
  • the reaction mixture can be filtered and the filtrate concentrated to dryness in vacuo, or the reaction mixture can be quenched in water and the intermediate product either filtered or extracted with a water immiscible solvent such as methylene chloride or ethyl acetate. Removal of the extracting solvent provides the desired product. Frequently, the residual can be induced to crystallize by trituration with an organic solvent, and further purified by recrystallization or column chromatography.
  • a water immiscible solvent such as methylene chloride or ethyl acetate.
  • the second step of the sequence leading to the products of the present invention consists of combining one molar equivalent of the appropriate 2-chloro-4- aminoquinazoline with either two molar equivalents of an amine, R 3 R 4 NH, or one equivalent of said amine and one equivalent of a tertiary amine-acid scavenger as described above in a reaction-inert solvent such as ethoxyethoxyethanol, butanol, amyl alcohol or
  • the reaction mixture can be cooled to room temperature and treated with a 1-N solution of an appropriate acid, such as hydrochloric acid to give a precipitate of the desired product as the hydrochloride salt.
  • an appropriate acid such as hydrochloric acid
  • the acid addition salt does not precipitate the free base product can be isolated by chromatographing the crude material on silica gel using an eluant such as chloroform, ethyl acetate, diethyl ether, methanol methylene chloride, ethanol or mixtures thereof and subsequently converted to the acid addition salt product.
  • the products are isolated by removing the eluting solvents in vacuo. Purification of the product can be done by recrystallization.
  • Generation of the free base from an acid addition salt can readily be carried out by treating an aqueous solution or suspension of the salt with at least one equivalent of an organic or inorganic base followed by extraction of the free base product with a water immiscible solvent such as ethyl acetate or methylene chloride. Removal of the solvent gives the desired base.
  • a water immiscible solvent such as ethyl acetate or methylene chloride. Removal of the solvent gives the desired base.
  • Compounds of formula I are inhibitors of the functions of P-glycoprotein, particularly human mdr 1 protein or P-glycoprotein related and membrane
  • Compounds enclosed in general formula I are useful in combination chemotherapy of cancer, malaria, viral infections such as AIDS, in therapy of septic shock syndrome or inflammation and may be useful in enhancing the tissue penetration of drugs where the penetration of these xenobiotics is limited due to the presence of P-glycoprotein or P-glycoprotein related functional proteins. Compounds of formula I increase the
  • the compounds of the present invention are evaluated as potentiators of chemotherapeutic agents using a Cellular Drug Retention Assay. This assay was designed to study the effect of compounds on cellular retention of radiolabeled drug. In this case
  • KBV1 cells are routinely grown in tissue culture as monolayers in DMEM high glucose medium containing 1 ug/ml vinblastine 10% heat inactivated fetal calf serum and supplemented with Glutamine, Pen-Strep and Garamycin.
  • the assay protocol (described below) should be applicable, with minor modifications, to a wide variety of cell lines grown in tissue culture.
  • trypsin/EDTA collect detached cells and transfer to scintillation vial. Rinse wells once with 0.5 ml of buffered saline and add to same vial containing cells;
  • Results are expressed as T/C and ED3x values as defined below:
  • T/C pmoles Adr per 10E6 cells treated with test agent/
  • Specific cpm [sample cpm - background cpm]
  • Specific activity [cpm/total cone, of Adr]
  • pmoles Adr [specific cpm/specific activity]
  • pmoles Adr per 10E6 cells [(pmoles Adr per well/number of cells per well) x 10E6 cells]
  • Such agents can include adriamycin, daunomycin, aclacinomycin A, actinomycin C, actinomycin D,
  • mithramycin toyomycin, vinblastine, maytansine, bruceantin, homoharintonin, anguindin, neocarcino- statin, mitomycin C and anthramycin.
  • the compounds of the present invention can be administered with, 24 hours before or up to 72 hours after the administration of the chemotherapeutic agents. When administered with said agents, they can be taken either separately or coadministered in the same formulation.
  • compositions comprising at least one of the compounds of formula I and optionally a chemotherapeutic agent, together with a pharmaceutically acceptable vehicle or diluent.
  • Such compositions are generally formulated in a conventional manner utilizing solid or liquid vehicles or diluents as appropriate to the mode of desired administration: for oral administration, in the form of tablets, hard or soft gelatin capsules, suspensions, granules, powders and the like, and, for parenteral administration, in the form of injectable solutions or suspensions, and the like.
  • a compound of formula I is given in an amount of about 0.5-100 mg/kg/day, in single or divided doses.
  • a more preferred dosage range is 2-50 mg/kg/day, although in particular cases, at the discretion of the attending physician, doses outside the broader range may be required.
  • the preferred route of administration is generally oral, but parenteral administration (e.g. intramuscular, intravenous, intradermal) will be preferred in special cases, e.g., where oral absorption is impaired as by disease, or where the patient is unable to swallow.
  • parenteral administration e.g. intramuscular, intravenous, intradermal
  • the present invention is illustrated by the following examples, but is not limited to the details or scope thereof.
  • dimethylacetamide was added 23.1 g of 1,2,3,4-tetra- hydro-6,7-dimethoxyisoquinoline in 300 ml of dry
  • Y 1 and Y 2 H; m.p. 199-201°C, M + 440.20.
  • Q 1 7-CH 3 O;
  • Q 2 H;
  • A -(CH 2 ) 2 -;
  • W (-);
  • n 0;
  • R, R 4 , R 5 H;
  • Q 6-CH 3 O;
  • Q 1 7-CH 3 O;
  • Q 2 H;
  • Q 1 7-CH 3 O;
  • Q 2 H;
  • A -(C H 2 ) 2 -;
  • W (-);
  • n 0;
  • Y 2 4-CH 3 O; m.p. 176.5-178.5°C, M + 577.40.
  • R C 2 H 5 O-;
  • R 4 , R 5 H;
  • Q 6-CH 3 O;
  • Q 1 , Q 2 H;
  • R C 2 H 5 O-;
  • R 4 , R 5 H;
  • Q 7-CH 3 O;
  • Q 1 8-CH 3 O;
  • R 3 NR 4 m.p. 181-182°C
  • R 3 NR 4 CHCH 2 CH 2 NH- m.p. 224-225°C M + 531.20
  • R 3 NR 4 CHCH 2 CH 2 NH- m.p. 226-229°C M + 531.20
  • R 3 NR 4 m.p. 181-183oC
  • R 3 NR 4 m.p. 154-156°C
  • R 3 NR 4 m.p. 170-171°C M + 573.20
  • R 3 NR 4 m.p. 233-235oC
  • R 3 NR 4 m.p 133-135.5°C M + 555.00
  • R 3 NR 4 m.p. 158-159°C (free base)
  • R 3 NR 4 m.p. 214-217oC M + 574.3
  • R 3 NR 4 m.p 163-167°C
  • R 3 NR 4 m.p. 155-156°C M + 478.00
  • R 3 NR 4 m.p. 225-235°C M + 500.00
  • R 3 NR 4 C 2 H 5 O(CH 2 ) 2 NH m.p. 185-186°C
  • R 3 NR 4 m.p. 240-242°C M + 560.00
  • R 3 NR 4 m.p. 232-233°C
  • R 3 NR 4 m.p. 229-230°C
  • R 3 NR 4 m.p. 200-202oC
  • R 3 NR 4 (CH 3 OCH 2 CH 2 ) 2 ) N- m.p . oC
  • R 3 R 4 N 3,4-(CH 3 O) 2 C 6 H 3 (CH 2 ) 2 NH
  • R 3 R 4 N 2-ClC 6 H 4 (CH 2 ) 2 NH
  • R 3 R 4 N 2-ClC 6 H 4 (CH 2 ) 2 NH
  • R 3 R 4 N 2-ClC 6 H 4 (CH 2 ) 2 NH
  • R 3 R 4 N 3,4-(CH 3 O) 2 C 6 H 3 (CH 2 ) 2 NH
  • R 3 R 4 N 2,3-(CH 3 O) 2 C 6 H 3 (CH 2 ) 2 NH
  • R 3 R 4 N 3,4-(CH 3 O) 2 C 6 H 3 (CH 2 ) 2 NH
  • R 3 R 4 N 2,3-(CH 3 O) 2 C 6 H 3 (CH 2 ) 2 NH
  • R 3 R 4 N 2,3-(CH 3 O) 2 C 6 H 3 (CH 2 ) 2 NH
  • R 3 R 4 N 2-ClC 6 H 4 (CH 2 ) 2 NH
  • R 3 R 4 N 3,4-(CH 3 O) 2 C 6 H 3 (CH 2 ) 2 NH
  • R 3 R 4 N 2,3-(CH 3 O) 2 C 6 H 3 (CH 2 ) 2 NH
  • R 3 R 4 N 2-ClC 6 H 4 (CH 2 ) 2 NH
  • R 3 R 4 N 3,4,5- (CH 3 O) 3 C 6 H 2 (CH 2 ) 2 NH
  • R 5 3,4-(CH 3 O) 2 C 6 H 3 CH 2 ;
  • Q 6-CH 3 O;
  • Q 1 7-CH 3 O;
  • R 5 3,4-(CH 3 O) 2 C 6 H 3 CH 2 ;
  • Q 6-CH 3 O;
  • Q 1 7-CH 3 O;
  • R 3 R 4 N 2,3-(CH 3 O) 2 C 6 H 3 (CH 2 ) 2 NH
  • R 3 R 4 N 3,4-(CH 3 O) 2 C 6 H 3 (CH 2 ) 2 NH
  • R 3 R 4 N 3,4-(CH 3 O) 2 C 6 H 3 (CH 2 ) 2 NH
  • R 3 R 4 N 3,4-(CH 3 O) 2 C 6 H 3 (CH 2 ) 2 NH
  • R 3 R 4 N 3,4-(CH 3 O) 2 C 6 H 3 (CH 2 ) 2 NH
  • R 3 R 4 N 2,4-(CH 3 O) 2 C 6 H 3 CH 2 NH;
  • R 3 R 4 N C 6 H 11 NH
  • R 3 R 4 N 3,4-(CH 3 O) 2 C 6 H 3 (CH 2 ) 2 NH; m.p. 193.5-194.5°C M + 544.3.
  • R 5 H; m.p. 150-153°C.
  • R 1 R 2 N C 2 H 5 O(CH 2 ) 2 m.p. 91-94°C.

Abstract

2,4-Diaminoquinazoline derivatives as potentiators of chemotherapeutic agents in the treatment of cancer.

Description

QUINAZOLINES DERIVATIVES FOR
ENHANCING ANTITUMOR ACTIVITY
Background of the Invention
This invention relates to 2,4-diaminoquinazolines and their use as sensitizers of tumor cells to anticancer agents.
In cancer chemotherapy the effectiveness of anticancer drugs is often limited by the resistance of tumor cells. Some tumors such as of the colon, pancreas, kidney and liver are generally innately resistant, and other responding tumors often develop resistance during the course of chemotherapy. The phenomena of multidrug resistance (MOR) is
characterized by the tumor cell's cross-resistance to structurally unrelated drugs. The drugs which are the target of resistance include adriaraycin, daunomycin, vinblastine, vincristine, actinomycin D and etoposide. The resistance cells are often associated with over- expression of the mdrl gene. This gene product is a family of 140-220 kd trans-membrane phosphoglycoprotein (P-glycoprotein) which functions as an ATP-dependent efflux pump. Thus, it has been postulated that this efflux mechanism keeps the intracellular level of the anticancer drug low, allowing the tumor cells to survive.
In recent years various substances such as verapamil, nifedipine and diltiazem have been used in in vitro experimental systems to reverse the MDR phenomena. More recently some of these agents have been tested clinically as MDR reversing agents. Little efficacy has been observed with verapamil or trifluoro- perazine. Thus, there is a need for an effective MDR reversing agent.
The 2,4-diaminoquinazolines are prepared by known methods utilizing 2,4-dichloroguinazolines [Postovskii and Goncharova, Zh. Obshch. Khim., 32, 3323 (1962)]. Curd et al. (J. Chem. Soc, 1947, 775) reported the synthesis of 2,4-dichloroquinazolines from the
corresponding 2,4 (1H, 3H)quinazolinedione. The
Wellcome Foundation discloses 2,4-diaminoquinazolines of general structure D as antibacterials [GB patent 806772 (1958)3. Hess [US 3,511,836 (1970)] patented compounds of structures E, F, and G as antihypertensive agents. Wijbe [GB patent 1,390,014 (1975)] patented a process for compounds of structure H and these
compounds are claimed to be antibacterials. Lacefield [US patent 3,956,495 (1976)] describes compounds of the general formula I as antithrombotic agents. Crenshaw
[US patent 4,098,788 (1978)] patented a process for the production of compounds of formula J. Hess [European Patent 0,028,473 (1981)] describes chloro- and alkoxy- substituted 2,4-diaminoquinazolines of formula K. Ife et al. describe compounds of general structur L as inhibitors of gastric acid secretion [WO 89/0527
(1989)]. Compounds of structures M and N were
published as phosphodiesterase inhibitors [Miller, J. Med. Chem., 28, 12 (1985)]. Richter et al. published compounds of structur O as inhibitors of dihydrofolate reductase [J. Med. Chem., 17, 943 (1974)]. In search of compounds with herbicidal activity Miki et al.
reported the synthesis of 2,4-dialkglaminoquinazolines (P) (Chem. Pharm. Bull. 30, 2313 (1982)]. Arylazido- prazosin (Q) has been shown to bind to P-glycoprotein [Safa et al., Biochem. Biophys. Res. Comm. 166, 259 (1990)].
Figure imgf000005_0001
Figure imgf000006_0001
Summary of the Invention
The compound of the present invention are of the formula
Figure imgf000007_0001
or a pharmaceutically acceptable acid addition salt thereof where X and X1 are each hydrogen, alkyl of one to four carbon atoms, iodo, bromo, nitro, chloro, fluoro, methylthio, amino, alkylamino of one to three carbon atoms, methyl- sulfinyl, aminomethyl, (CH3)2S®, dialkylaxinomethyl of three to seven carbon atoms, hydroxymethyl, morpholino, thio- morpholino, benzoylamino, substituted benzoylamino wherein said substituent is azido, methoxy, methyl, fluoro, chloro or trifluoromethyl, alkanoylamino having two to four carbon atoms, 4-methylpiperazino, piperazino, piperidino, pyrrolidino, dialkylamino of two to six carbon atoms or alkoxy of one to four carbon atoms; X2 is hydrogen, alkyl of one to four carbon atoms or alkoxy of one to four carbon atoms; X and X1 together are ethylenedioxy or methylenedioxy; R1 is alkyl having one to four carbon atoms, cycloalkyl of three to seven carbon atoms, alkoxyalkyl said alkoxy having one to three carbon atoms and said alkyl having two to three carbon atoms or benzodioxan-2-ylmethyl; R2 is hydrogen, alkyl of one to eight carbon atoms or benzyl; R1 and R2 when taken together with the nitrogen atom to which they are attached form (a) a moiety of the formula
Figure imgf000008_0001
where Q is hydrogen, alkoxy of one to three carbon atoms, hydroxy, alkanoylamino having two to four carbon atoms, alkyl of one to three carbon atoms, bromo, iodo, chloro, fluoro, nitro, morpholino, amino, alkylamino of one to three carbon atoms or dialkylamino of two to six carbon atoms, Q1 is hydrogen, fluoro, chloro, bromo, alkyl having one to three carbon atoms or alkoxy having one to three carbon atoms, Q2 is hydrogen or alkoxy of one to three carbon atoms, Q1 and Q2 together are methylenedioxy or ethylenedioxy, R is hydrogen, alkyl having one to four carbon atoms or alkoxy of one to three carbon atoms, m is an integer of 0-2, p is an integer of 1-2, R 5 is hydrogen or dialkoxybenzyl said alkoxy having one to three carbon atoms and R and R5 together are alkylene having one to three carbon atoms,
(b) 1, 2, 3, 4-tetrahydro-beta-carbol-2-yl or
(c) piperidino of the formula
Figure imgf000008_0002
where R6 is pyridylmethoxy, alkoxyalkyleneoxy said alkoxy having one to three carbon atoms and said alkylene having two to three carbon atoms or benzoxazol-2-ylmethyl
(d) octahydroisoindol-2-yl or
(e) decahydroisoquinol-2-yl;
R3 is
(a) cycloalkyl of three to seven carbon atoms,
(b) benzodioxan-2-ylmethyl
(c) aralkyl of the formula
Figure imgf000009_0001
wherein n is an integer of 1 or 0, W is O, S or a chemical bond, A is alkylene of one to four carbon atoms, Y is hydrogen, alkyl of one to three carbon atoms, fluoro, chloro, bromo, hydroxy, alkoxy of one to three carbon atoms, benzyloxy, nitro, dimethylamino or amino, Y1 is hydrogen, alkoxy of one to three carbon atoms, chloro, fluoro, hydroxy or benzyloxy, Y2 is hydrogen or alkoxy of one to three carbon atoms and Y and Y1 together are methylenedioxy or ethylenedioxy,
(d) aralkyl of the formula
Figure imgf000009_0002
where R7 is hydroxy, alkoxy of one to three carbon atoms or C6H5(CH2)t0, n is 1, t is an integer of 1 or 0, A is alkylene of one to four carbon atoms, Q3 and Q4 are each hydrogen or alkoxy of one to three carbon atoms and Q3 and Q4 together are methylenedioxy or ethylenedioxy,
(e) pyridylalkyl said alkyl having one to four carbon atoms,
(f) alkoxyalkyl said alkoxy having one to three carbon atoms and said alkyl having two to three carbon atoms,
(g) indolylalkyl of the formula
Figure imgf000010_0001
where A is alkylene of one to four carbon atoms, Q3 and Q4 are each hydrogen or alkoxy of one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy,
(h) tetrahydronaphthalene of the formula
Figure imgf000010_0002
where A is alkylene of one to four carbon atoms, Q3 and Q4 are each hydrogen or alkoxy of one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy; (i) aralkanol of the formula
Figure imgf000011_0003
where W is O, S or a chemical bond and Q3 is hydrogen or alkoxy of one to three carbon atoms,
(j) 2,3-dihydro-2-hydroxyinden-1-yl,
(k) aracycloalkyl of the formula
Figure imgf000011_0001
wherein A is alkylene having one to four carbon atoms, Q3 and Q4 are each hydrogen or alkoxy having one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy,
(1) indene of the formula
Figure imgf000011_0002
wherein Q3 and Q4 are each hydrogen or alkoxy of one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy,
(m) naphthyl or
(n) 1-methylpyrrol-2-yl;
R4 is hydrogen or alkyl of one to eight carbon atoms and R3 and R4 taken together with the nitrogen atom to which they are attached form
(a) a tetrahydroisoquinoline of the formula
Figure imgf000012_0001
where Q3 and Q4 are each hydrogen or alkoxy of one to three carbon atoms and Q3 and Q4 together are methylenedioxy or ethylenedioxy,
(b) piperidino of the formula
Figure imgf000012_0002
wherein R8 is benzyl, alkoxyalkyleneoxy said alkoxy having from one to three carbon atoms and said alkylene having two to three carbon atoms or alkyl sulfonamide of the formula
Figure imgf000012_0003
where R9 is alkyl of one to four carbon atoms
(c) 3-methyl-3-phenylpiperidino or
(d) piperazino of the formula
Figure imgf000013_0002
where R10 is hydrogen, alkoxycarbonyl of two to six carbon atoms, acyl of one to six carbon atoms, hydroxyalkoxy- carbonyl of three to six carbon atoms, furoyl, benzoxazol-2- yl, pyrimid-2-yl or benzodioxan-2-ylcarbonyl.
A preferred group of compounds are those where X and X1 are each alkoxy of one to four carbon atoms, X2 is hydrogen, R1 and R2 when taken together with the nitrogen atom to which they are attached form a moiety of the formula
Figure imgf000013_0001
where Q1 is alkoxy of one to three carbon atoms, R and R5 are each hydrogen, p is 1, m is 0, R3 is aralkyl of the formula
Figure imgf000014_0001
where Y1 and Y2 are each methoxy, n is 0 , W is a chemical bond, A is ethylene and R4 is hydrogen. Especially preferred within this group are the compounds where X is 6 -methoxy, X1 is 7-methoxy, Q is 5-hydroxy, Q1 is 6-methoxy, Q2 is hydrogen, Y is hydrogen, Y1 is 2-methoxy and Y2 is 3 -methoxy, where X is 6-methoxy, X1 is 7-methoxy, Q is 6-methoxy, Q1 is 7 -methoxy, Q2 is hydrogen, Y is hydrogen, Y1 is 3-methoxy and Y2 is 4 -methoxy, where X is 6-methoxy, X1 is 7-methoxy, Q is 7-methoxy, Q1 is 8-methoxy, Q2 is hydrogen, Y is hydrogen, Y1 is 2 -methoxy and Y2 is 3-methoxy, where X is 6-methoxy, X1 is 7-methoxy, Q and Q2 are each hydrogen, Q1 is 6-methoxy, Y is hydrogen, Y1 is 3-methoxy and Y2 is 4-methoxy, where X is 6-methoxy, X1 is 7-methoxy, Q is 5-methoxy, Q1 is 6-methoxy, Q2 is hydrogen, Y is hydrogen, Y1 is 3 -methoxy and Y2 is 4-methoxy, where X is 6-methoxy, X1 is 7 -methoxy, Q is 6-methoxy, Q1 is 7-methoxy, Q2 is hydrogen, Y is 2-bromo, Y1 is 4 -methoxy and Y2 is 5-methoxy, where X is 6-methoxy, X1 is 7-methoxy, Q is 6-methoxy, Q1 is 8-methoxy, Q2 is hydrogen, Y is hydrogen, Y1 is 3-methoxy and Y2 is 4-methoxy and where X is 6-methoxy, X1 is 7 -methoxy, Q is 7-methoxy, Q1 is 8-methoxy, Q2 is hydrogen, Y is hydrogen, Y1 is 3-methoxy and Y2 is 4 -methoxy.
A second group of preferred compounds are those where X1 and X2 are each hydrogen, R1 and R2 when taken together with the nitrogen atom to which they are attached form a moiety of the formula
Figure imgf000015_0001
where Q and Q1 are each alkoxy of one to three carbon atoms, Q2 is hydrogen, R and R5 are each hydrogen, p is 1, m is 0, R3 is aralkyl of the formula
Figure imgf000015_0002
wherein Y2 is hydrogen, n is 0, W is a chemical bond and A is ethylene and R4 is hydrogen. Especially preferred within this group are compound where X is 5-methoxy, Q is 6-methoxy, Q1 is 7-methoxy, Y is 2-chloro and Y1 is hydrogen, where X is 5-chloro, Q is 6-methoxy, Q1 is 7-methoxy, Y is 2-chloro and Y1 is hydrogen, where X is 5-methyl, Q is 6-methoxy, Q1 is 7-methoxy, Y is 3-methoxy and Y1 is 4-methoxy and where X is 6-dimethylamino, Q is 6-methoxy, Q1 is 7-methoxy, Y is 3-methoxy and Y1 is 4-methoxy.
A third group of preferred compounds are those where X and X1 are each alkoxy of one to four carbon atoms, X2 is hydrogen, R1 and R2 when taken together with the nitrogen atom to which they are attached form a moiety of the formula
Figure imgf000016_0001
where Q2 is hydrogen, R5 is hydrogen, p is 1-2, R3 is aralkyl of the formula
Figure imgf000016_0002
where Y and Y1 are each alkoxy of one to three carbon atoms, Y2 is hydrogen, n is 0, W is a chemical bond, A is ethylene and R4 is hydrogen. Especially preferred within this group are compounds where X is 6-methoxy, X1 is 7-methoxy, Q and Q1 are each hydrogen, p is 1, R is methoxy, m is 0, Y is 2-methoxy and Y1 is 3-methoxy, where X is 6-methoxy, X1 is 7-methoxy, Q and Q1 are each hydrogen, p is 2, R is hydrogen, m is 1, Y is 3-methoxy and Y1 is 4-methoxy and where X is 6-methoxy, X1 is 7-methoxy, Q is 7-amino, Q1 is hydrogen, R is hydrogen, m is 0, p is 1, Y is 3-methoxy and Y1 is 4-methoxy.
A fourth group of preferred compounds those where X and X1 are each alkoxy of one to four carbon atoms, R1 and R2 when taken together with the nitrogen atom to which they are attached form a moiety of the formula
Figure imgf000017_0001
where Q and Q1 are each alkoxy of one to three carbon atoms, Q2 is hydrogen, R and R5 are each hydrogen, p is 1, m is 0, R3 is aralkyl of the formula
Figure imgf000017_0002
where Q3 and Q4 are each alkoxy of one to three carbon atoms, R7 is methoxy, n is 1, A is methylene and R4 is hydrogen.
Especially preferred within this group is the compound where
X is 6-methoxy, X1 is 7-methoxy, Q is 6-fluoro, R is methoxy,
Q3 is 2-methoxy and Q4 is 3-methoxy.
A fifth group of preferred compounds are those where X1 is alkoxy of one to four carbon atoms, X2 is hydrogen, R1 and R2 when taken together with the nitrogen atom to which they are attached form a moiety of the formula
Figure imgf000018_0001
where Q and Q1 are each alkoxy of one to three carbon atoms, Q2 is hydrogen, p is 1, m is 0, R3 is aralkyl of the formula
Figure imgf000018_0002
where Y2 is hydrogen, n is 0, W is a chemical bond, A is ethylene and R, is hydrogen. Especially preferred within this group is the compound where X is 6-chloro, X1 is 7-methoxy, Q is 6-methoxy, Q1 is 7-methoxy, R and R5 are each hydrogen, Y is 3-methoxy and Y1 is 4-methoxy.
The present invention also includes a method of inhibiting a P-glycoprotein in a mammal in need of such treatment which comprises administering to said mammal a P-glycoprotein inhibiting amount of a compound of formula I. Preferred is the method where the mammal is a human suffering from cancer and said compound is administered before, with or after the administration to said human of an anticancer effective amount of a chemotherapeutic agent. Also included is a pharmaceutical composition for administration to a mammal which comprises a P-glycoprotein inhibiting amount of a compound of formula I, a pharmaceutically acceptable carrier and, optionally, an anticancer effective amount of a chemotherapeutic agent.
As previously indicated, the compounds of formula I form pharmaceutically acceptable acid addition salts. Said pharmaceutically acceptable acid addition salts include, but are not limited to, those with HCl, HBr, HNO3, H2SO4, H3PO4, CH3SO3H, p-CH3C6H4SO3H, CH3CO2H, gluconic acid, tartaric acid, maleic acid and succinic acid. In the case of those compounds of the formula (I) which contain a further basic nitrogen, it will, of course, be possible to form diacid addition salts (e.g., the dihydrochloride) as well as the usual monoacid addition salt.
As one skilled in the art recognized, compounds of formula I have the potential for containing asymmetric carbon atoms. All these potential isomers are considered within the scope of the present invention.
The terms "alkyl" and "alkylene" are meant to embrace both straight chained and branched members.
Detailed Description of the Invention
Compounds of the present invention are prepared with the reaction of a 2,4-dichloroquinazoline with an equivalent of an appropriate amine, R1R2NH, followed by the reaction of the product, a 2-chloro-4-amino- quinazoline derivative, with a second equivalent of an appropriate amine, R3R4NH.
In a more detailed description of the procedure, one molar equivalent of an optionally substituted
2,4-dichloroquinazoline and one molar equivalent of a tertiary amine-acid scavenger, such as triethylamine, N-methylmorpholine or diethylisopropylamine and one molar equivalent of an amine, R1 R2NH, are combined in an anhydrous solvent such as dimethylacetamide, dioxane or N-methyl-2-pyrrolidone and maintained at from 0°C to about 25°C for a period of 1 to 48 hours.
The reaction mixture can be filtered and the filtrate concentrated to dryness in vacuo, or the reaction mixture can be quenched in water and the intermediate product either filtered or extracted with a water immiscible solvent such as methylene chloride or ethyl acetate. Removal of the extracting solvent provides the desired product. Frequently, the residual can be induced to crystallize by trituration with an organic solvent, and further purified by recrystallization or column chromatography.
The second step of the sequence leading to the products of the present invention consists of combining one molar equivalent of the appropriate 2-chloro-4- aminoquinazoline with either two molar equivalents of an amine, R3R4NH, or one equivalent of said amine and one equivalent of a tertiary amine-acid scavenger as described above in a reaction-inert solvent such as ethoxyethoxyethanol, butanol, amyl alcohol or
cyclohexanol for a period of 5 minutes to several hours at reaction temperatures of 100-200°C.
The reaction mixture can be cooled to room temperature and treated with a 1-N solution of an appropriate acid, such as hydrochloric acid to give a precipitate of the desired product as the hydrochloride salt.
Other acids would give the corresponding acid addition salt. In instances where the acid addition salt does not precipitate the free base product can be isolated by chromatographing the crude material on silica gel using an eluant such as chloroform, ethyl acetate, diethyl ether, methanol methylene chloride, ethanol or mixtures thereof and subsequently converted to the acid addition salt product. The products are isolated by removing the eluting solvents in vacuo. Purification of the product can be done by recrystallization.
Generation of the free base from an acid addition salt can readily be carried out by treating an aqueous solution or suspension of the salt with at least one equivalent of an organic or inorganic base followed by extraction of the free base product with a water immiscible solvent such as ethyl acetate or methylene chloride. Removal of the solvent gives the desired base.
Compounds of formula I are inhibitors of the functions of P-glycoprotein, particularly human mdr 1 protein or P-glycoprotein related and membrane
associate proteins which are participating in the transport of xenobiotics or proteins across membranes e.g., cell membranes of eukariotic and proeukariotic origin e.g., pmfdr, however not exclusive or restricted to these examples.
Compounds enclosed in general formula I are useful in combination chemotherapy of cancer, malaria, viral infections such as AIDS, in therapy of septic shock syndrome or inflammation and may be useful in enhancing the tissue penetration of drugs where the penetration of these xenobiotics is limited due to the presence of P-glycoprotein or P-glycoprotein related functional proteins. Compounds of formula I increase the
activity/efficacy of adriamycin, daunomycin, etoposide, epipodophyllotoxin congoners, actinomycin D, emetin, vincristin, vinblastin, chloroquine, antracyclin antibiotics and of drugs which are structurally and functionally related to the above mentioned examples, in particular when the activity of these drugs has been shown to be limited due to the presence and function of P-glycoprotein, e.g. human mdr 1 protein or
P-glycoprotein related proteins.
The compounds of the present invention are evaluated as potentiators of chemotherapeutic agents using a Cellular Drug Retention Assay. This assay was designed to study the effect of compounds on cellular retention of radiolabeled drug. In this case
14C-adriamycin retention by multidrug resistant human carcinoma cells, KBV1, is measured.
KBV1 cells are routinely grown in tissue culture as monolayers in DMEM high glucose medium containing 1 ug/ml vinblastine 10% heat inactivated fetal calf serum and supplemented with Glutamine, Pen-Strep and Garamycin.
The assay protocol (described below) should be applicable, with minor modifications, to a wide variety of cell lines grown in tissue culture.
Assay Protocol:
(1) Seed replicate 6-well tissue culture plates with 1.2 x 10E6 cells per 2 ml per well in absence of Vinblastine;
(2) Incubate 24 hrs at 37 degrees in humidified incubator (5% CO2);
(3) Aspirate off the spent media and overlay monolayers with 2 ml/well of fresh medium that is 2 uM in Adriamycin (2 uM unlabeled Adriamycin + 20000 cpm of 14C-Adr) and the test agent at concentrations varying from 0 to 100 uM;
(4) Following incubation for 3 hours at 37 degrees in humidified incubator, remove media and wash monolayers twice with 2 ml of ice-cold buffered saline;
(5) Detach monolayers using 0.5 ml of
trypsin/EDTA, collect detached cells and transfer to scintillation vial. Rinse wells once with 0.5 ml of buffered saline and add to same vial containing cells;
(6) Add 5 ml of Beckman Ready-Safe scintillation fluid to vial, vortex and determine radioactivity per sample using a scintillation counter (10 minutes per sample);
(7) For background control: pre-incubate
monolayers at 4 degrees for 15 minutes then remove media and add fresh ice-cold media containing Adr (see step 3). Following incubation for 3 hours at 4 degrees remove media and wash monolayers twice with 2 ml ice-cold buffered saline, then proceed as in step 5;
(8) Results are expressed as T/C and ED3x values as defined below:
T/C = pmoles Adr per 10E6 cells treated with test agent/
pmoles Adr per 10E6 untreated cells
ED3x = concentration of test agent that
produces a 3 fold increase in cellular accumulation of radiolabeled Adr, i.e. T/C = 3.
Calculations:
Specific cpm = [sample cpm - background cpm] Specific activity = [cpm/total cone, of Adr] pmoles Adr = [specific cpm/specific activity] pmoles Adr per 10E6 cells = [(pmoles Adr per well/number of cells per well) x 10E6 cells]
As previously mentioned compounds of the present invention and salts thereof are useful in potentiating the anticancer effects of chemotherapeutic agents.
Such agents can include adriamycin, daunomycin, aclacinomycin A, actinomycin C, actinomycin D,
mithramycin, toyomycin, vinblastine, maytansine, bruceantin, homoharintonin, anguindin, neocarcino- statin, mitomycin C and anthramycin.
The compounds of the present invention can be administered with, 24 hours before or up to 72 hours after the administration of the chemotherapeutic agents. When administered with said agents, they can be taken either separately or coadministered in the same formulation.
The compounds of the present invention whether taken separately or in combination with an anti-cancer agent, are generally administered in the form of pharmaceutical compositions comprising at least one of the compounds of formula I and optionally a chemotherapeutic agent, together with a pharmaceutically acceptable vehicle or diluent. Such compositions are generally formulated in a conventional manner utilizing solid or liquid vehicles or diluents as appropriate to the mode of desired administration: for oral administration, in the form of tablets, hard or soft gelatin capsules, suspensions, granules, powders and the like, and, for parenteral administration, in the form of injectable solutions or suspensions, and the like.
For use in the potentiation of anti-cancer agents in a mammal, including man, a compound of formula I is given in an amount of about 0.5-100 mg/kg/day, in single or divided doses. A more preferred dosage range is 2-50 mg/kg/day, although in particular cases, at the discretion of the attending physician, doses outside the broader range may be required. The preferred route of administration is generally oral, but parenteral administration (e.g. intramuscular, intravenous, intradermal) will be preferred in special cases, e.g., where oral absorption is impaired as by disease, or where the patient is unable to swallow. The present invention is illustrated by the following examples, but is not limited to the details or scope thereof.
EXAMPLE 1
2-(N-Methyl-3,4-dimethoxyphenethylamino)-4-(1,2,3,4- tetrahydro-6,7-dimethoxyisoquinol-2-yl)-6,7-dimethoxy- quinazoline hydrochloride (I: X = 6-CH3O; X1 = 7-CH3O;
X2 = H; R1R2N = 6,7-(CH3O)2-1,2,3,4-tetrahydroiso- quinol-2-yl; R3 = 3,4(CH3O) 2phenethyl; and R4 = CH3)
-----------------------------------------------------------------------------------------------------
A. 2-chloro-4-(1,2,3,4-tetrahydro-6,7-dimethoxy- isoquinol-2-yl)-6,7-dimethoxyquinazoline
To 26.59 g of 2,4-dichloro-6,7-dimethoxyquina- zoline and 20.39 g of triethylamine in 250 ml of warm
dimethylacetamide was added 23.1 g of 1,2,3,4-tetra- hydro-6,7-dimethoxyisoquinoline in 300 ml of dry
dimethylacetamide and the reaction mixture stirred at
room temperatures under exclusion of moisture for 16
hours. The precipitate was filtered and the filtrate
concentrated to dryness under reduced pressure. The
residual product was recrystallized from methanol,
40.6 g, m.p. 183-186ºC.
B. 2-(N-methyl-3,4-dimethoxyphenethylamino)-4- (1,2,3,4-tetrahydro-6,7-dimethoxyisoquinol-2-yl)-
6,7-dimethoxyquinazoline hydrochloride
A mixture of 840 mg of the product of Example 1A
and 1.28 g of N-methyl-3,4-dimethoxyphenethylamine in 1
ml of ethoxyethoxyethanol was stirred under an inert
atmosphere for 1 hour at 150°C. The reaction mixture
was cooled to room temperature and passed through a
column packed with 30 g of silica gel under 2.5
atmosphere of nitrogen pressure with 500 ml of
chloroform. The product was eluted with 2% (V:V)
methanol in chloroform. The fraction containing the product (Rf 0.47 10% methanol in chloroform on silica) was concentrated in vacuo and the crude residue crystallized from IN hydrochloric acid in methanol- water (1:1, V:V), 271 mg, m.p. 190-192°C, M+ = 575.40.
EXAMPLES 2-71
Employing the procedure of Example 1 and starting with the appropriate starting reagents, the following compounds were prepared as their hydrochloride salt unless otherwise indicated:
Figure imgf000028_0001
Example 2: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O; Y = 4-CH3O and Y2 = H; m.p. 194-195°C, M+ 560.20.
Example 3: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4, R5 = H; Q, Q1, Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O; Y1 = 4-CH3O; and Y2 = H; m.p. 185-186°C, M+ 500.30. Example 4: X = 6-C2H5O; X1 = 7-C2H5O; X2 = H; R, R4, R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O; Y1 = 4-CH3O; and Y2 = H; m.p. 121-122°C, M+ 588.30.
Example 5: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4, R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y, Y1 and Y2 = H; m.p. 219-226°C,
M+ 500.20.
Example 6: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 - H; Q, Q1, Q2 = H; A = -(CH2)2-; W = (-) ; n = 0; Y,
Y1 and Y2 = H; m.p. 199-201°C, M+ 440.20.
Example 7: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q, Q1, Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 2-CH3O; Y1 and Y2 = H; m.p. 140-142°C, M+ 471.00.
Example 8: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-;
W = (-) ; n = 0; Y = 2-CH3O; Y and Y2 = H;
m.p. 232.5-234°C, M+ 531.00.
Example 9: X = 6-CH3O; X1 = 7-CH3O; X = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
A = -CH2CH(CH3)-; W = 0; n = 1 ; Y, Y1 and Y2 = H;
m.p. 105-107°C, M+ 545.00.
Example 10: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4, R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-;
W = 0; n = 0; Y = 2-1; Y1 = 4-1; and Y2 = 6-1;
m.p. 175-180°C, M+ 894.90.
Example 11: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-; w = (-); n = 0; Y = 4-CH3O; Y1 and Y2 = H;
m.p. 113-115.5°C, M+ 531.00. Example 12: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q, Q1, Q2 = H; A = -(CH2)2-; W = (-); n = 0;
Y 5= 4-CH3O; Y1 and Y2 = H; m.p. 204-205°C, M+ 471.00.
Example 13: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q = 7-CH3O; Q2 = H; A = -(CH2)2-;
W = (-); n = 0; Y = 2-Cl; Y1 and Y2 = H;
m.p. 130-132.5°C, M+ 535.00.
Example 14: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4, R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-;
W = (-) ; n = 0; Y = 3-CH3O; Y = 4-CH3O; and
Y2 = 5-CH3O; m.p. 217-218°C, M+ 591.10.
Example 15: X, X1, X2 = H; R, R4, R5 = H; Q = 6-CH3O;
Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-; W = (-); n = 0;
Y = 3-CH3O; Y1 = 4-CH3O; and Y2 = H; m.p. 108-109.5°C
(free base), M+ 501.3.
Example 16: X, X1, X2 = H; R, R4, R5 = H; Q, Q1,
Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O;
Y1 = 4-CH3O; and Y = H; m.p. 123.5-124.5°C (free base), M+ 441.20.
Example 17: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-;
W = S; n = 1; Y, Y1 and Y2 = H; m.p. 112-114°C, M+
533.2.
Example 18: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-; W = (-) ; n = 0; Y = 4-NO2; Y1 and Y2 = H;
m.p. 210-213°C, M+ 546.3. Example 19: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(C H2)2 -;
W = (-); n = 0; Y = 2-CH3O; Y = 3-CH3O; and Y2 = H; m.p. 108-111°C, M+ 561.00.
Example 20: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(C H2)2 -;
W = (-); n = 0; Y = 3-CH3O; Y1 = 5-CH3O; and Y2 = H; m.p. 234-235°C, M+ 561.40.
Example 21: X = 6-CH3O; X1 = 7-CH3O; X = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-;
W = (-); n = 0; Y = 4-Cl; and Y1 and Y2 = H;
m.p. 111-113°C, M+ 535.30.
Example 22: X = 6-CH3O; X1 = 7-CH3O; X = H; R, R4, R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-;
W = (-); n = 0; Y = 2-CH3O; Y1 = 5-CH3O; and Y2 = H; m.p. 201-203°C, M+ 561.40.
Example 23: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
R, R4, R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
A = -(CH2)2-; W = (-); n = 0; Y = 4-CH3; and Y1 and
Y2 = H; m.p. 230-323°C, M+ 515.4.
Example 24: X = 6-CH3O; X1 = 7-CH3O; X2 = 8-CH3O; R,
R4, R5 = H; Q; Q = 6-CH3O; Q1 = 7-CH3O; Q = H;
A = -(CH2)2-; W = (-); n = 0; X = 3-CH3O; Y1 = 4-CH3O; and Y2 = H; m.p. 180-182°C, M+ 591.10.
Example 25: X = 6-CH3O; X1 = 7-CH3O; X = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q = H; A = -(C H2)2 -;
W = (-); n = 0; Y = 4-C2H5O; Y1 and Y2 = H;
m.p. 105-210°C, M+ 545.00. Example 26: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4, R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O; Y and Y2 = H;
m.p. 109-111°C, M+ 531.00.
Example 27: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-;
W = (-); n = 0; Y = 2-Br; Y1 = 4-CH3O; and Y2 = 5-CH3O; m.p. 176-179°C, M+ 641.10.
Example 28: X, X1, X2 = H; Q = 6-CH3O; Q1 = 7-CH3O;
Q2 = H; R, R4, R5 = H; A = -(C H2)2 -; W = (-); n = 0;
Y = 2-CH3O; Y1 = 3-CH3O; and Y2 = H; m.p. 208-209°C, M+ 501.10.
Example 29: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4, R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-;
W = (-); n = 0; Y = 3-Cl; Y1 = 4-Cl; and Y2 = H;
m.p. 135-138°C, M+ 569.30.
Example 30: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R,
R4 = H; R5 = 3,4-(CH3O)C6H,CH2-; Q = 6-CH3O;
Q1 = 7-CH3O; Q2 = H; A = -(C H2)2 -; W = (-); n = 0;
Y = 3-CH3O; Y1 = 4-CH3O; and Y2 = H; m.p. 156-159°C,
M+ 711.40.
Example 31: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4, R5 = H; Q = 6-CH3O; Q1= 7-CH3O; Q2 = H; A = -(CH2)2-; W = O; n = 0; Y = 2-Cl; Y1 and Y2 = H; m.p.
126.5-128°C, M+ 535.00.
Example 32: X = 6-CH3O; X = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q = H; A = -(CH2)2-; W = 0; n = 0; Y = 4-Cl; Y1 and Y2 = H; m.p. 218-219°C, M+ 535.00.
SUBSTITUTE Example 33 : X = 6-CH3O; X = 7-CH3O; X2 = H; R, R4 , R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = - (CH2)2-;
W = 0; n = 0; Y = 4-Cl; Y and Y2 = H; m.p. 120-122°C,
M+ 551.30.
Example 34: X = 6-CH 3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(C H2)2 -;
W = (-); n = 0, Y + Y1 = 3,4-CH2OCH2-; and Y2 = H; m.p.
231.5-233°C, M+ 545.30.
Example 35: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(C H2)2 -;
W = 0; n = 0; Y = 4-CH3O; Y1 and Y2 = H;
m.p. 115-119°C, M+ 547.30.
Example 36: X = 6-CH3O; X1 - 7-CH3O; X2 = H; R, R4, R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -CH2-;
W = (-); n = 0; Y = 2-CH3O; Y1 = 3-CH3O; and
Y2 = 4-CH3O; m.p. 176.5-178.5°C, M+ 577.40.
Example 37: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 4-OH; Y1 = 3-C2H5O; and Y2 = H;
138-142°C, M+ 561.30.
Example 38: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q = H; A = -(CH2)2-; W = (-); n = 0; Y = 4-OH; Y1 = 3-CH3O; and Y2 = H;
m.p. 232-235°C, M+ 547.30.
Example 39: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q, Q1, Q2 = H; A = -(CH2)2-; W = (-); n = 0;
Y = 3-CH3O; Y1 and Y2 = H; m.p. 125.5-141.4°C,
M+ 471.20. Example 40: X = 6-CH3O; X = 7-CH3O; X = H; R, R4, R5 = H; Q = 6-CH3O; Q 1 = 7-CH3O; Q2 = H; A = -(CH2)2-;
Y = 3-C6H5CH2O; Y1 = 4-C6H5CH2O; and Y2 = H;
m.p. 204-206°C, M+ 713.60.
Example 41: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q, Q1, Q2 = H; A = -(CH2)2-; W = (-); n = 0;
Y = 2-CH3O; Y1 = 3-CH3O; and Y2 = H;
m.p. 189.5-191.5°C, M 501.30.
Example 42: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 7-CH3O; Q = 8-CH3O; Q2 = H; A = -(CH2)2-;
W = (-); n = 0; Y = 3-CH3O; Y = 4-CH3O; and Y2 = H; m.p. 195-196°C, M+ 561.30.
Example 43: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4, R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-;
W = (-); n = 0; Y = 3-CH3O; Y1 = 4-CH3O; and Y2 = H; m.p. 189-191°C, M+ 515.30.
Example 44: X = 6-CH3O; X1, X2 = H; R, R4, R5 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 2-CH3O; Y1 = 3-CH3O; and Y2 = H; m.p.
212-215°C, M+ 531.00.
Example 45: X = 6-CH3O; X1, X2 = H; R, R4, R5 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(-CH2)2-;
W = (-); n = 0; Y = 2-Cl; Y1 and Y2 = H;
m.p. 221-223°C, M+ 505.20.
Example 46: X = 6-CH3O; X1, X2 = H; R, R4, R5 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-;
W = (-); n = 0; Y = 3-CH3O; Y1 = 4-CH3O; and Y2-H;
m.p. 206-208°C, M+ 531.20. Example 47: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
A = -CH(CH3)CH2CH2-; W = (-); n = 0; Y, Y1, Y2 = H; m.p. 198-200°C, M+ 529.00.
Example 48: X = 6-CH3O; X1 = 7-C :Hι3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -CH2-;
W = (-); n = 0; Y = 4-CH3O; Y and Y = H;
m.p. 155-156°C, M+
Example 49: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q = 7-CH3O; Q2 = H; A = -CH2-;
W = (-); n = 0, Y, Y1, R1 = H; m.p. 169-171°C;
M+ 487.00.
Example 50: X = 6-F; X1 = 7-F; X2 = H; R, R4, R5 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O; Y1 = 4-CH3O; and Y2 = H;
m.p. 112-114°C, M+ 537.3.
Example 51: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 4-F; Y1 and Y2 = H; m.p. 225-227°C,
M+ 519.30.
Example 52: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R,
R5 = H; R4 = C2H5; Q = 6-CH3; Q1 = 7-CH3O; Q2 = H;
A = -CH2-; W = (-); n = 0; Y = 4-C2H5O; Y1 and Y2 = H; m.p. 201-203°C, M+ 545.40.
Example 53: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R,
R5 = H; R4 = C2H5; Q, Q1, Q2 = H; A = -CH2-; W = (-); n = 0; Y = 4-C2H5O-; Y1 and Y2 = H; m.p. 167-168°C,
M+ 485.30. Example 54: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4, R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 4-OH; Y1 and Y2 = H;
m.p. 151-153°C, M+ 517.30.
Example 55: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-NO2; Q1, Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O; Y1 = 4-CH3O; and Y2 = H;
m.p. 212-214°C, M+ 546.30.
Example 56: X, X1 = H; X2 = 8-CH3O; R, R4, R. = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 2-CH3O; Y1 = 3-CH3O; and Y2 = H;
m.p. 90-92°C (free base), M+ 531.30.
Example 57: X = 6-CH3; X1, X2 = H; R, R4, R5 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 2-Cl; Y1 and Y2 = H; m.p. 212-214°C,
M+ 489.00
Example 58: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 6-CH3O; Q1, Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O; Y1 = 4-CH3O; and Y2 = H;
m.p. 160-162°C, M+ 531.00.
Example 59: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 5-CH3O; C1 , Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O; Y1 = 4-CH3O; and Y2 = H;
m.p. 197-198.5°C, M+ 531.00.
Example 60: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 - H; Q = 6-CH3O; Q1 = 8-CH3O, Q = H; A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O; Y = 4-CH3O; and Y2 = H; m.p. 146-149ºC, M+ 561.30. Example 61: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 7-C1; Q1, Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O; Y1 = 4-CH3O; and Y2 = H;
m.p. 190-193°C, M+ 535.00.
Example 62: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 5-CH3O; Q , Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 2-CH3O; Y1 = 3-CH3O; and Y2 = H;
m.p. 199-200°C, M+ 531.00.
Example 63: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q = 5-CH3O; Q , Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 2-Cl; Y1and Y2 = H; m.p. 210-211°C,
M+ 505.30.
Example 64: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
R = C2H5O; R4, R5 = H; Q = 6-CH3O; Q1 = 7-CH3O;
Q2 = 8-CH3O; A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O;
Y1 = 4-CH3O; and Y2 = H; m.p. 138-140°C, M+ 635.00.
Example 65: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R = CH3O;
R4, R5 = H; Q = 7-CH3O; Q1 = 8-CH3O; Q2 = H;
A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O; Y1 = 4-CH3O; and Y2 = H; m.p. 178-180°C, M+ 591.50.
Example 66: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
R = C2H5O-; R4, R5 = H; Q = 6-CH3O; Q1, Q2 = H;
A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O; Y1 = 4-CH3O; and Y2 = H; m.p. 86-88°C, M+ 575.40.
Example 67: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
R = C2H5O-; R4, R5 = H; Q = 7-CH3O; Q1 = 8-CH3O;
Q2 = H; A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O;
Y1 = 4-CH3O; and Y2 = H; m.p. 168-169°C, M+ 605.40. Example 68 : X = H; X1 = 7-CH3O; X2 = 8-CH3O; R, R4 ,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = - (C H2)2 -;
W = (-) ; n = 0 ; Y = 3-CH3O; Y1 = 4-CH3O; and Y2 = H ; m.p. 138-140°C , M+ 561 . 40.
Example 69 : X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4 ,
R5 = H; Q = 6-CH3O; Q = 7-CH3O; Q2 = 8-CH3O;
A = -(CH2)2-; W = (-); n = 0; Y = 3-CH3O; Y1 = 4-CH3O; and Y2 = H; m.p. 157-158°C, M+ 591.30.
Example 70: X = H; X1 = 7-CH3O; X2 = 8-CH3O; R, R4,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; A = -(CH2)2-;
W = (-); n = 0; Y = 3-CH3O; Y = 4-CH3O; and Y2 = H; m.p. 147.5-151°C, M+ 561.40.
Example 71: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R4,
R5 = H; Q, Q1, Q2 = H; A = -(C H2)2 -; W = (-) ; n = 0;
Y = 3-CH3O; Y1 = 4-OH; and Y2 = H; m.p. 169-171.5°C,
M 487.20
EXAMPLES 72-106
Using the procedure of Example 1, and starting with the requisite reagents, the following compounds were prepared as their hydrochloride salts unless
indicated otherwise:
Figure imgf000039_0003
Example 72: X = 6-CH3O; X1 = 7-CH3O; X2 = H; Q, Q1,
Q2 = H;
R3NR4 = m.p. 181-182°C
Figure imgf000039_0001
M+ 452.20
Example 73: X = 6-CH3O; X = 7-CH3O; X2 = H; Q, Q1,
Q2 = H;
R3NR4 = CHCH2CH2NH- m.p. 224-225°C
Figure imgf000039_0002
M+ 531.20 Example 74: X 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 7-CH3O; Q2 = H;
R3NR4 = CHCH2CH2NH- m.p. 226-229°C
Figure imgf000040_0003
M+ 531.20
Example 75: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 181-183ºC
M+ 572.30
Figure imgf000040_0002
Example 76: X = 6-CH3O; X 7-CH3O; X2 = H; Q, Q1, Q 2 = H;
R3NR4 = m.p. 154-156°C
M+ 512.10
Figure imgf000040_0001
Example 77: X 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 7-CH3O; Q2 = H;
R3NR4 = m.p. 145.5-148°C
Figure imgf000041_0001
M+ 527.00 Example 78: X = 6-CH3O; X1 = 7-CH3CH2CH2O; X = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 170-171°C
Figure imgf000041_0002
M+ 573.20
Example 79: X 6-C2H5O; X1 = 7-C2H5O; X = H;
Q = 6-CH3O; Q1 7-CH3O; Q = H;
R3NR4 = m.p. 196-200°C
M+ 573.20
Figure imgf000041_0003
Example 80: X 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 233-235ºC
M+ 540.00
Figure imgf000042_0001
Example 81: X 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p 133-135.5°C
Figure imgf000042_0002
M+ 555.00
Example 82: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p 225-227°C
M+ 570.20
Figure imgf000042_0003
Example 83: X = 6-CH3O; X1 = 7-CH..O; X = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 200-221°C (dec)
M+ 571.00
Figure imgf000043_0001
Example 84: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 186.5-188°C
(free base)
Figure imgf000043_0002
M+ 502.20 Example 85: X = 6-CH3O; X1 = 7-CH3O; X = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 202.5-204.5°C
M+ 513.20
Figure imgf000043_0003
Example 86: X, X1, X2 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 158-159°C
Figure imgf000044_0001
(free base)
M+ 484.53 Example 87: X = 6-CH3O; X 7-CH3O; X2 = 8-CH3O;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 214-217ºC
Figure imgf000044_0002
M+ 574.3
Example 88: X, X1, X2 = H; Q = 6-H3O; Q1 = 7-CH3O;
Q2 = H;
R3NR4 = m.p. 148-150°C
(free base)
Figure imgf000044_0003
M+ 512.2 Example 89: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p 163-167°C
M+ 587.30
Figure imgf000044_0004
Example 90: X = 6-CH3O; X1 = 7-CH3O X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 134-136.5°C
M+ 577.40
Figure imgf000045_0001
Example 91: X = 6-CH3O; X1 - 7-CH3O; X = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 211-213°
M+ 591.20
Figure imgf000045_0002
Example 92: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 214-216°C
M 591.30
Figure imgf000045_0003
Example 93: X = 6-CH3; X1, X2 = H; Q = 6-CH3O;
Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 192-194°C
M+ 499.20
Figure imgf000046_0001
Example 94: X = 6-CH3O; X1 = 7-CH3O; X2 = H; Q, Q1,
Q2 = H;
R3NR4 = m.p. 155-156°C
Figure imgf000046_0002
M+ 478.00
Example 95: X = 6-CH3O; X1 = 7-CH3O; X2 = H; Q, Q1, Q2 = H;
R3NR4 = m.p. 225-235°C
Figure imgf000046_0003
M+ 500.00
Example 96: X 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 7-CH3O; Q2 = H;
R3NR4 = C2H5O(CH2)2NH m.p. 185-186°C
M+
Example 97: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 240-242°C
Figure imgf000047_0001
M+ 560.00
Example 98: X 6-CH3O; X1 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 7-CH3O; Q2 = H;
R3NR4 = m.p. 238.5-240°C
M+ 545.00
Figure imgf000047_0002
Example 99: X 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 232-233°C
Figure imgf000048_0001
M+ 561.00
Example 100: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 229-230°C
M+ 572.00
Figure imgf000048_0002
Example 101: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = m.p. 165-168 dec°C
M+ 628.00
Figure imgf000048_0003
Example 102: X = 6-CH3O; X1 = 7-CH3O; X = H; Q, Q1,
Q = H;
R3NR4 = m.p. 206-210°C
M+ 469.30
Figure imgf000049_0002
Example 103: X = 6-CH3O; X1 = 7-CH3O; X2 = H; Q = H; Q1 = 7-CH3O; Q2 = 8-CH3O;
R3NR4 = m.p. 200-202ºC
M+ 591.00
Figure imgf000049_0001
Example 104: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H;
R3NR4 = M+ 548.30
Figure imgf000049_0003
Example 105 : X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O ; Q1 = 7-CH3O; Q2 = H;
R3NR4 = - m.p. 168-170°C
Figure imgf000050_0001
M+ 582. 30
Example 106 : X = 6-CH3O; X1 = 7-CH 3O; X2 = H;
Q = 6-CH3O ; Q1 = 7-CH3O; Q2 = H;
R3NR4 = (CH3OCH2CH2 ) 2 ) N- m.p . ºC
M 513 . 00
EXAMPLE 107
2-(3,4-Dimethoxyphenethylamino)-4-(2,3,4,5-tetrahydro- 2-benzoazep-2-yl)-6,7-dimethoxyquinazoline hydro- chloride (I: X = 6-CH3O; X1 = 7-CH3O; R1R2N = 2,3,4,5- tetrahydro-2-benzazep-2-yl;
R3 = 3,4-(CH3O)2C6H3(CH2)2-; and R4 = H)
A. 2-chloro-4-(2,3,4,5-tetrahydrobenzazep-2-yl)-6,7- dimethoxyquinazoline
A mixture of 1.0 g of 2,3,4,5-tetrahydro-2- benzazepine, 1.76 g of 2,4-dichloro-6,7-dimethoxyquina- zoline and 1.0 g of triethylamine in 25 ml of methylene chloride was stirred at room temperature under nitrogen for three hours. An additional 290 mg of the
benzazepine was added and stirring continued over 48 hours. The reaction mixture was diluted with 100 ml of methylene chloride and the organic solution washed successively with 1N hydrochloric acid (3 x 75 ml), water (2 x 75 ml), a saturated sodium bicarbonate solution (2 x 75 ml), water (2 x 75 ml) and a brine solution (1 x 75 ml). The organic phase was separated, dried over sodium sulfate and concentrated to a foam, 2.15 g. The residue was treated with reluxing methanol and cooled in a refrigerator. The resulting solids were filtered and dried, 1.84 g. A small sample was recrystallized from methanol, m.p. 164-165°C.
B. 2-(3,4-dimethoxyphenethylamino)-4-(2,3,4,5-tetra- hydrobenzazep-2-yl)-6,7-dimethoxyquinazoline hydrochloride
A mixture of 1.109 g of the product of Example 107A, 543 mg of 3,4-dimethoxyphenethylamine and 387 mg of diisopropylethylamine in 1.1 g ethoxyethoxyethanol was stirred under nitrogen at 170°C for five hours.
The reaction mixture was cooled to room temperature and diluted with 5 ml of methylene chloride. This solution was chromatographed without pressure on 60 g of silica gel using methylene chloride as the eluant, taking 15 fractions. Fractions 3-6 were combined and the elution continued under pressure with 2% methanol-methylene chloride, taking 14 fractions. Fractions 8-12 were combined and concentrated to give an oil which was dissolved in 6 ml of 1N hydrogen chloride in methanol. The resulting solids were filtered and dried, 679 mg, m.p. 226-228°C. Fractions 3-6 when carried through the same procedure gave 170 mg of the hydrochloride salt. Anal. Calc'd for C30H34N4O4 · HCl: C, 65.4; H,
10.2; N, 6.4..
Found: C, 65.3; H, 10.1; N, 6.5.
EXAMPLES 108-138
Employing the procedure of Example 107 and starting with the appropriate reagents, the following compounds were prepared:
Figure imgf000052_0001
Example 108: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H, m = 0; p = 1;
NR3R4 =
Figure imgf000052_0002
m.p. 205-206°C M+ 531.2. Example 109: X = 6-CH3O; X = 7-CH3O X2 = H; R, R5 = H; Q, Q1 = H; Q2 = 8-CH3O; m = 0; p = 1;
R3R4N = 3,4-(CH3O)2C6H3 (CH2)2NH
m.p. 187-188°C M+ 531.0.
Example 110: X = 6-CH3; X1, X2 = H; R, R5 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; m = 0; p = 1;
R3R4N = 2-ClC6H4 (CH2)2NH
m.p. 156-157°C M+ 489.0.
Example 111: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R5 = H; Q = 5-CH3O; Q1 = 6-CH3O; Q2 = H; m = 0; p = 1; R3R4N = 3,4-(CH3O)2C6H3(CH2)2NH
m.p. 175-177°C
M+ 561.1.
Example 112: X = 6-Cl; X1, X2 = H; R, R5 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; m = 0; p = 1;
R3R4N = 2-ClC6H4 (CH2)2NH
m.p. 241-242°C
M+ 509.03.
Example 113: X = 5-Cl; X1, X2 = H; R, R5 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; m = 0; p = 1;
R3R4N = 2-ClC6H4 (CH2)2NH
m.p. 166-167°C
M+ 509.0.
Example 114: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 5-CH3O; Q1 = 6-CH3O; Q2 = H; R, R5 = H; m = 0;
p = 1; R3R4N = 2,3-(CH3O)2C6H3(CH2)2NH
m.p. 209°C
M+ 561.27. Example 115: X = 5-Cl; X1, X2 - H; R, R5 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; m = 0; p = 1;
R3R4N = 3,4-(CH3O)2C6H3(CH2)2NH
m.p. 106-107°C
M+ 535.3.
Example 116: X = 5-Cl; X1, X2 = H; R, R5 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; m = 0; p = 1;
R3R4N = 2,3-(CH3O)2C6H3(CH2)2NH
m.p. 200-202°C
M+ 535.20.
Example 117: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R5 = H; Q = H; Q1 = 7-CH3O; Q2 = 8-CH3O; m - 0; p = 1; R3R4N = 2,3-(CH3O)2C6H3(CH2)2NH
m.p. 194.5-195.5°C
M+ 561.0.
Example 118: X = 5-Cl; X1, X2 = H; R, R5 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; m = 0; p = 1;
R3R4N = 3,4-(CH3O)2C6H3(CH2)2NH
m.p. 197-198°C
M+ 531.4.
Example 119: X = 6-Cl; X1, X2 = H; R, R5 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; m = 0; p = 1;
R3R4N = 2,3-(CH3O)2C6H3(CH2)2NH
m.p. 214-215°C
M+ 535.40.
Example 120: X = 5-Cl; X1, X2 = H; R, R5 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; m = 0; p = 1;
R3R4N = 2,3-(CH3O)2C6H3(CH2)2NH
m.p. 178-179°C
M+ 531.4. Example 121: X = 5-Cl; X1, X2 = H; R, R5 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; m = 0; p = 1;
R3R4N = 2-ClC6H4(CH2)2NH
m.p. 178-179°C
M+ 505.3.
Example 122: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; m = 0; p = 1; R3R4N = 2-I-4,5-(CH3O)2C6H2(CH2)2NH
m.p. 216-217°C (free base)
M+ 687.0.
Example 123: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R5 = H; Q = H; Q1 = 7-CH3O; Q2 = 8-CH3O; m = 0; p = 1; R3R4N = 2-ClC6H4(CH2)2NH
m.p. 197-198°C
M+ 547.1.
Example 124: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
R = CH3O; R5 = H; Q = 6-F; Q1, Q2 = H; m = 0; p = 1; R3R4N = 3,4-(CH3O)2C6H3(CH2)2NH
m.p. 215-217°C
M+ 548.6.
Example 125: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R5 = H; Q, Q1 = H; Q2 = 7-CH3; m = 0; p = 1;
R3R4N = 3,4-(CH3O)2C6H3(CH2)2NH
m.p. 182-183°C
M+ 515.3.
Example 126: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R5 = H; Q, Q1, Q2 = H; m = 1; p = 1;
R3R4N = 2,3-(CH3O)2C6H3(CH2)2NH
m.p. 222-223°C
M+ 515.3. Example 127: X = 6-CH3O; X = 7-CH3O; X2 = H; R, R5 = H; Q, Q1, Q2 = H; m = 1; p = 1;
R3R4N = 2-ClC6H4(CH2)2NH
m.p. 218-219°C M+ 489.2.
Example 128: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R,
R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; m = 0; p = 1;
R3R4N = 3,4,5- (CH3O)3C6H2(CH2)2NH
m.p. 142-150°C
M+ 591.4.
Example 129: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R = H;
R5 = 3,4-(CH3O)2C6H3CH2; Q = 6-CH3O; Q1 = 7-CH3O;
Q = H; m = 0; p = 1; R3R4N = 2-ClC6H4 (CH2)2NH
m.p. 234-235°C
M+ 671.2.
Example 130: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R = H;
R5 = 3,4-(CH3O)2C6H3CH2; Q = 6-CH3O; Q1 = 7-CH3O;
Q2 = H; m = 0; p = 1; R3R4N = 2, 3- (CH3O)2C6H3 (CH2)2NH m.p. 144-145°C
M+ 697.3.
Example 131: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
R = CH3O; R5 = H; Q, Q1, Q2 = H; m = 0; p = 1;
R3R4N = 2,3-(CH3O)2C6H3(CH2)2NH
m.p. 120-123°C
M+ 531.2.
Example 132: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
R = CH3O; R5 = H; Q, Q1, Q2 = H; m = 0; p = 1;
R3R4N = 3,4-(CH3O)2C6H3(CH2)2NH
m.p. 206-208°C
M+ 531.6. Example 133: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R5 = H; Q, Q1, Q2 = H; m = 1; p = 1;
R3R4N = 3,4-(CH3O)2C6H3(CH2)2NH
m.p. 217-219°C M+ 515.5.
Example 134: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R5 = H; Q, Q2 = H; Q1 = 7-NH2; m = 1; p = 1;
R3R4N = 3,4-(CH3O)2C6H3(CH2)2NH
m.p. 213-217°C (free base) M+ 530.2.
Example 135: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R = H; R-. = 3,4-(CH3O)2C6H3CH2; Q = 6-CH3O; Q1 = 7-CH3O;
Q2 = H; m = 0; p = 1; R3R4N = 3 ,4- (CH3O)2C6H3 (CH2)2NH m.p. 208-209°C
M+ 711.4.
Example 136: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
R = CH3O; R5 = H; Q = H; Q1 = 7-CH3O; Q2 = 8-CH3O; m = 0; p = 1; R3R4N = 3, -(CH3O)2C6H3CH (CH3O) (CH2)2NH m.p. 159-161°C (free base)
M+ 621.4.
Example 137: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R5 = H; Q = 5-OH; Q1 = 6-CH3O; Q2 = H; m = 0; p = 1; R3R4N = 2,3-(CH3O)2C6H3(CH2)2NH
m.p. 190-200°C
M+ 547.0.
Example 138: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R, R5 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; m = 0; p = 1; R3R4N = 2-Br-4,5-(CH3O)2C6H2(CH2)2NH
m.p. 176-179°C
M+ 641.0. Example 139: X = 5-CH3; X1, X2 = H; R, R5 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; m = 0; p = 1;
R3R4N = 3,4-(CH3O)2C6H3(CH2)2NH
m.p. 141-142°C M+ 515.0.
EXAMPLES 140-147
Using the procedure of Example 107 and starting with the necessary reagents, the following compounds were prepared:
Figure imgf000058_0001
Example 140: X-CH3O; X1 - 7-CH3O; X2 = H; R1R2N R3R4N =
Figure imgf000058_0002
Figure imgf000058_0003
m.p. 204-207°C M+ 545.2. Example 141: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R1R2N =
C2H5O(CH2)O R3R4 = 2, 4- (CH3O)2C6H3CH2NH;
Figure imgf000059_0001
m.p. 117-119° (free base) M+ 527.0.
Example 142: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R1R2N =
R3R4N = 2,4-(CH3O)2C6H3CH2NH;
Figure imgf000059_0002
m.p. 146-147°C (free base) M+ 621.4.
Example 143: X, X1, X2 = H; R1R2N = C6H11NH-;
R3R4N = C6H11NH;
m.p. 162-165°C (free base)
M+ 325.0.
Example 144: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R1R2N =
Figure imgf000059_0003
m.p. 215-217°C (free base) M+ 591.0. Example 145: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R1R2N = 3 4
Figure imgf000060_0001
v
m.p. 220°C;
M+ 507.0.
Example 146: X = 6-N(CH3)2; X1 X2 = H; R1R2N =
; R3R4N = 3,4-(CH3O)2C6H3(CH2)2NH;
Figure imgf000060_0002
m.p. 193.5-194.5°C M+ 544.3.
Example 147: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R1R2N =
R3R4N = ;
Figure imgf000060_0003
Figure imgf000060_0004
m.p. 156-158°C M+ 579.3.
PREPARATION A
Employing the procedure of Example 1A and starting with appropriate reagents, the following intermediates were prepared:
Figure imgf000061_0001
Compound 1: X = 6-CH3O; X1 = 7-C3H7O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; R, R5 = H; m.p.
120-121°C.
Compound 2: X = 6-C2H5O; X 1 = 7-C2H5O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; R, R5 = H; m.p.
161-162°C.
Compound 3: X = 6-CH3O; X1 = 7-CH3O; X2 = H; Q, Q1,
Q2 = H; R, R5 = H; m.p. 169-171°C.
Compound 4: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; R, R5 = H; m.p.
183-186°C.
Compound 5: X, X1, X2 = H; Q = 6-CH3O; Q1 = 7-CH3O;
Q2 = H; R, R5 = H;; m.p. 126-126.5°C. Compound 6: X = 6-CH3O; X1 = 7-CH3O; X2 = 8-CH3O;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; R, R5 = H; m.p.
130-131°C.
Compound 7: X = 6-CH3O X1 = 7-C-H3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O Q2 = H;
R5 = 3,4-(CH3O)2C6H3CH2 R = H; m.p. 154-156.5°C.
Compound 8: X = 6-CH3O X1 = 7-CH3O; X2 = H; Q = H;
Q1 = 7-CH3O; Q2 = 8-CH3O; R, R5 = H ; m.p . 162-163 ºC . Compound 9 : X = 6-CH3O; X1 , X2 = H; Q = 6-CH3O;
Q1 = 7-CH3O; Q2 - H; R, R5 = H ; m.p . 132-134 °C.
Compound 10: X = 6-CH3; X1, X2 = H; Q = 6-CH3O;
Q1 = 7-CH3O; Q2 = H; R, R5 = H; m.p. 133-135°C.
Compound 11: X, X1, X2 = H, Q, Q1, Q2 = H; R, R5 = H; m.p. 130-131°C.
Compound 12: X = 6-F; X1 = 7-F; X2 = H; Q = 6-CH3O;
Q1 = 7-CH3O; Q2 = H; R, R5 = H; m.p. 219-220°C.
Compound 13: X = 6-CH3O; X1 = 7-CH3O; X2 = H; Q,
Q2 = H; Q1 = 7-NO2; R, R5 = H; m.p. 210-212°C.
Compound 14: X, X1 = H; X2 = 8-CH3O; Q = 6-CH3O;
Q1 = 7-CH3O; Q2 = H; R, R5 = H; m.p. 147-149°C.
Compound 15: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1, Q2 = H; R, R5 = H; m.p. 181-184°C.
Compound 16: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 5-CH3O; Q1 = 6-CH3O; Q2 = 7-CH3O; R, R5 = H; m.p.
152-153°C.
Compound 17 : X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 5-CH3O; Q1 , Q2 = H; R, R5 = H; m. p . 144. 5-146 °C .
Compound 18 : X = 6-CH3O; X1 = 7-CH3O ; X2 = H;
Q = 7-NH2 ; Q1 , Q2 = H; R, R5 = H; m. p . 123-126 °C . Compound 19: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 7-Cl; Q1, Q2 = H; R, R5 = H; m.p. 187-189°C.
Compound 20: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = 8-CH3O; R = C2H5O;
R5 = H; m.p. 150-153°C.
Compound 21: X = 6-CH3O; X1 = 7-CH3O; X2 = H; Q = H;
Q1 = 7-CH3O; Q2 = 8-CH3O; R = CH3O; R5 = H; m.p.
138-140ºC.
Compound 22: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1, Q2 = H; R = C2H5O; R5 = H; m.p.
140-142°C.
Compound 23: X = 6-CH3O; X1 = 7-CH3O; X2 = H; Q = H;
Q1 = 7-CH3O; Q2 = 8-CH3O; R = C2H5O; R5 = H; m.p.
161-164°C.
Compound 24: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = H; Q2 = 8-CH3O; R, R5 = H; m.p.
159-161°C.
Compound 25: X = H; X1 = 7-CH3O; X2 = 8-CH3O;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = H; R, R5 = H; m.p.
143-143.5°C.
Compound 26: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 6-CH3O; Q1 = 7-CH3O; Q2 = 8-CH3O; R, R5 = H; m.p.
152-153°C.
Compound 27: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 7-CH3; Q1, Q2 = H; R, R5 = H; m.p. 169-170°C.
Compound 28: X = 5-Cl; X1, X2 = H; Q = 6-CH3O;
Q1 = 7-CH3O; Q2 = H; R, R5 = H; m.p. 161-162°C.
Compound 29 : X = 6-Cl ; X1 , X2 = H; Q = 6-CH3O;
Q1 = 7-CH3O; Q2 = H; R, R5 = H ; m. p . 144-145°C . Compound 30: X = 6-CH3O; X 1= 7-CH3O; X2 = H;
Q = 5-CH3O; Q1 = 6-CH3O; Q2 = H; R, R5 = H;
m.p. 138.5-139°C.
Compound 31: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
Q = 5-OH; Q1 = 6-CH3O; Q2 = H; R, R5 = H;
m.p. 221-223°C.
Compound 32: X = 5-CH3; X1, X2 = H; Q = 6-CH3O;
Q1 = 7-CH3O; Q2 = H; R, R5 = H; m.p. 174-175°C.
Compound 33: X = 6-CH3O; X1 = 7-CH3O; X2 = H; Q = H;
Q1 = 7-CH3O; Q2 = 8-CH3O; R = CH3O; R,. = H;
m.p. 138-140°C.
Compound 34: X = 6-CH3O; X1 = 7-CH3O; X2 = H; Q,
Q1 = H; Q2 = 8-CH3O; R, R5 = H; m.p. 204-205°C.
Compound 35: X = 6-CH3O; X1 = 7-CH3O; X2 = H; Q, Q1,
Q2 = H; R = CH3O; R5. = H; m.p. 162-165°C.
Compound 36: X = 6-CH3O; X1 = 7-CH3O; X2 = H; Q = 6-F;
Q1, Q2 = H; R = CH3O; R5 = H; m.p. 155-157°C.
Compound 37: X = 6-N(CH3)2; X1, X2 = H; Q = 6-CH3O; Q1 = 7-CH3O; Q = H; R, R5 = H; amorphous.
Compound 38: X = 6-CH3O; X1 = 7-CH3O; X2 = H; Q = 6-F;
Q1, Q2 = H; R = CH3O; R5 = H; m.p. 195-197°C.
PREPARATION B
The procedure of Example 1A was repeated starting with the required materials to give the following intermediates:
Figure imgf000065_0001
Compound 39: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R1R2N =
m.p. 241-243°C.
Figure imgf000065_0002
Compound 40: X = 6-CH3O; X1 = 7-CH3O; X2 = H;
R1R2N = C2H5O(CH2)2 m.p. 91-94°C.
Figure imgf000065_0003
Compound 41: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R1R2N=
m.p. 149-150°C
Figure imgf000065_0004
Compound 42: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R1R2N =
Figure imgf000066_0001
Compound 43: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R1R2N = m.p. 174-176°C.
Figure imgf000066_0002
Compound 44: X = 6-CH3O; X1 = 7-CH3O; X = H; R1R2N = m.p. 300°C.
Figure imgf000066_0003
Compound 45: X = 6-CH3O; X1 = 7-CH3O; X2 = H; R1R2N =
Figure imgf000067_0001
Compound 46: X, X1, X2 = H, R1R2N = C6H11NH; m.p. 85-89°C.

Claims

1. A compound of the formula
Figure imgf000068_0001
and a pharmaceutically acceptable acid addition salt thereof wherein X and X1 are each hydrogen, alkyl having one to four carbon atoms, alkoxy having one to four carbon atoms, bromo, iodo, nitro, amino, alkylamino having one to three carbon atoms, (CH3)2S⊕, aminomethyl, methylsulfinyl, dialkylaminomethyl having three to seven carbon atoms, methylthio, hydroxymethyl, benzoylamino, substituted benzoylamino wherein said substituent is azido, methoxy, methyl, fluoro, chloro or trifluoromethyl, alkanoylamino having two to four carbon atoms, 4-methylpiperazino, morpholino, thiomorpholino, piperazino, piperidino, pyrrolidino, dialkylamino having two to six carbon atoms, fluoro or chloro; X2 is hydrogen, alkyl having one to four carbon atoms or alkoxy having one to four carbon atoms; X and X1 together are ethylenedioxy or methylenedioxy; R1 is alkoxylalkyl said alkoxy having from one to three carbon atoms and said alkyl having two to three carbon atoms, cycloalkyl having three to seven carbon atoms, alkyl having one to four carbon atoms or benzodioxan-2-ylmethyl; R2 is hydrogen, alkyl having one to eight carbon atoms or benzyl; R1 and R2 when taken together with the nitrogen atom to which they are attached form
(a) a moiety of the formula
Figure imgf000068_0002
wherein Q is hydrogen, alkoxy having one to three carbon atoms, hydroxy, alkanoylamino having two to four carbon atoms, alkyl having one to three carbon atoms, bromo, iodo, fluoro, chloro, nitro, morpholino, amino, alkylamino having one to three carbon atoms or dialkylamino having two to six carbon atoms, Q1 is hydrogen, fluoro, chloro, bromo, alkyl having one to three carbon atoms or alkoxy having one to three carbon atoms and Q2 is hydrogen or alkoxy having one to three carbon atoms, Q1 and Q2 together are ethylenedioxy or methylenedioxy, R is hydrogen, alkyl having one to four carbon atoms or alkoxy having one to three carbon atoms, m is an integer of 0-2, p is an integer of 1-2, R5 is hydrogen or dialkoxybenzyl said alkoxy having one to three carbon atoms and R and R5 together are alkylene having one to three carbon atoms,
(b) 1,2,3,4-tetrahydro-beta-carbol-2-yl
(c) piperidino of the formula
Figure imgf000069_0002
wherein R6 is pyridylmethoxy, alkoxyalkyleneoxy said alkoxy having from one to three carbon atoms and said alkylene having from two to three carbon atoms or benzoxazol-2- ylmethyl
(d) octahydroisoindol-2-yl or
(e) decahydroisoquinol-2-yl;
R3 is
(a) cycloalkyl having three to seven carbon atoms, (b) benzodioxan-2-ylmethyl,
(c) aralkyl of the formula
Figure imgf000069_0001
wherein n is an integer of 1 or 0, W is 0, S or a chemical bond, A is alkylene having one to four carbon atoms, Y is hydrogen, alkyl having one to three carbon atoms, alkoxy having one to three carbon atoms, fluoro, chloro, bromo, hydroxy, benzyloxy, nitro, dimethylamino or amino, Y1 is hydrogen, alkoxy having one to three carbon atoms, chloro, fluoro, hydroxy or benzyloxy, Y2 is hydrogen or alkoxy having one to three carbon atoms and Y and Y1 together are ethylenedioxy or methylenedioxy,
(d) aralkyl of the formula
Figure imgf000070_0001
wherein R7 is hydroxy, alkoxy having one to three carbon atoms or C6H5(CH2)t-, n is 1, t is an integer of 0 or 1, A is alkylene having one to four caraon atoms, Q3 and Q4 are each hydrogen or alkoxy having one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy,
(e) pyridylalkyl said alkyl having from one to four carbon atoms,
(f) alkoxyalkyl said alkoxy having from one to three carbon atoms and said alkyl having two the three carbon atoms,
(g) indolylalkyl of the formula
Figure imgf000070_0002
wherein A is alkylene having one to four carbon atoms, Q3 and Q4 are each hydrogen or alkoxy having one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy,
(h) tetrahydronaphthalene of the formula
Figure imgf000071_0001
wherein A is alkylene having one to four carbon atoms, Q3 and Q4 are each hydrogen or alkoxy having one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy,
(i) aralkanol of the formula
Figure imgf000071_0002
wherein W is O, S or a chemical bond and Q3 is hydrogen or alkoxy having one to three carbon atoms,
(j) 2,3-dihydro-2-hydroxyinden-1-yl,
(k) aracycloalkyl of the formula
Figure imgf000071_0003
wherein A is alkylene having one to four carbon atoms, Q3 and Q4 are each hydrogen or alkoxy having one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy,
(1) indene of the formula
Figure imgf000071_0004
wherein Q3 and Q4 are each hydrogen or alkoxy having one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy,
(m) naphthyl or (n) 1-methylpyrrol-2-yl;
R4 is hydrogen or alkyl having one to eight carbon atoms, and R3 and R4 when taken together with the nitrogen atom to which they are attached form
(a) a tetrahydro isoquinoline of the formula
Figure imgf000072_0001
wherein Q3 and Q4 are each hydrogen or alkoxy having one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy,
(b) piperidino of the formula
Figure imgf000072_0004
wherein R8 is benzyl, alkoxyalkyleneoxy said alkoxy having from one to three carbon atoms and said alkylene having two to three carbon atoms or alkyl sulfonamide of the formula
Figure imgf000072_0002
wherein R9 is alkyl having from one to four carbon atoms,
(c) 3-methyl-3-phenylpiperidino or
(d) piperazino of the formula
Figure imgf000072_0003
wherein R10 is hydrogen, alkoxycarbonyl having from two to six carbon atoms, acyl having one to six carbon atoms, hydroxyalkoxy carbonyl having three to six carbon atoms, furoyl, benzoxazol-2-yl, pyrimid-2-yl or benzodioxan-2- carbonyl.
2. A compound of claim 1, wherein X and X1 are each alkoxy having one to four carbon atoms, X2 is hydrogen, R1 and R2 when taken together with the nitrogen atom to which they are attached form a moiety of the formula
Figure imgf000073_0001
wherein Q1 is alkoxy having one to three carbon atoms, R and R5 are each hydrogen, p is 1 and m. is 0, R3 is aralkyl of the formula
Figure imgf000073_0002
wherein Y1 and Y2 are each methoxy, n is 0, W is a chemical bond and A is ethylene and R4 is hydrogen.
3. The compound of claim 2, wherein X is 6-methoxy, X1 is 7-methoxy, Q is 5-hydroxy, Q1 is 6-methoxy, Q2 is hydrogen, Y is hydrogen, Y1 is 2-methoxy and Y2 is 3-methoxy.
4. The compound of claim 2, wherein X is 6-methoxy, X1 is 7-methoxy, Q is 7-methoxy, Q1 is 8-methoxy, Q2 is hydrogen, Y is hydrogen, Y1 is 3-methoxy and Y2 is 4-methoxy.
5. The compound of claim 2, wherein X is 6-methoxy, X1 is 7-methoxy, Q is 7-methoxy, Q1 is 8-methoxy, Q2 is hydrogen, Y is hydrogen, Y1 is 2-methoxy and Y2 is 3-methoxy.
6. The compound of claim 2, wherein X is 6-methoxy, X1 is 7-methoxy, Q and Q2 are each hydrogen, Q1 is 6-methoxy, Y is hydrogen, Y1 is 3-methoxy and Y2 is 4-methoxy.
7. The compound of claim 2, wherein X is 6-methoxy, X1 is 7-methoxy, Q is 5-methoxy, Q1 is 6-methoxy, Q2 is hydrogen, Y is hydrogen, Y1 is 3-methoxy and Y2 is 4-methoxy.
8. The compound of claim 2, wherein X is 6-methoxy, X1 is 7-methoxy, Q is 6-methoxy, Q1 is 7-methoxy, Q2 is hydrogen, Y is 2-bromo, Y1 is 4-methoxy and Y2 is 5-methoxy.
9. The compound of claim 2, wherein X is 6-methoxy, X1 is 7-methoxy, Q is 6-methoxy, Q1 is 8-methoxy, Q2 is hydrogen, Y is hydrogen, Y1 is 3-methoxy and Y2 is 4-methoxy.
10. The compound of claim 2, wherein X is 6-methoxy, X1 is 7-methoxy, Q is 6-methoxy, Q1 is 7-methoxy, Q2 is hydrogen, Y is hydrogen, Y1 is 3-methoxy and Y2 is 4-methoxy.
11. A compound of claim 1, wherein X1 and X2 are each hydrogen, R1 and R2 when taken together with the nitrogen atom to which they are attached form a moiety of the formula
Figure imgf000074_0001
wherein Q and Q1 are each alkoxy having one to three carbon atoms, Q2 is hydrogen, R and R5 are each hydrogen, p is 1 and m is 0, R3 is aralkyl of the formula
Figure imgf000074_0002
wherein Y2 is hydrogen, n is 0, W is a chemical bond and A is ethylene and R4 is hydrogen.
12. The compound of claim 11, wherein X is 5-methoxy, Q is 6-methoxy, Q1 is 7-methoxy, Y is 2-chloro and Y1 is hydrogen.
13. The compound of claim 11, wherein X is 5-chloro, Q is 6-methoxy, Q1 7-methoxy, Y is 2-chloro and Y1 is hydrogen.
14. The compound of claim 11, wherein X is 5-methyl, Q is 6-methoxy, Q1 is 7-methoxy, Y is 3-methoxy and Y1 is 4-methoxy.
15. The compound of claim 11, wherein X is 6-dimethyl- amino, Q is 6-methoxy, Q1 is 7-methoxy, Y is 3-methoxy and
Y1 is 4-methoxy.
16. A compound of claim 1, wherein X and X1 are each alkoxy having one to four carbon atoms, X2 is hydrogen, R1 and R2 when taken together with the nitrogen atom to which they are attached form a moiety of the formula
Figure imgf000075_0001
wherein Q2 is hydrogen, R5 is hydrogen and p is 1-2, R3 is aralkyl of the formula
Figure imgf000075_0002
wherein Y and Y1 are each alkoxy having one to three carbon atoms, Y2 is hydrogen, n is 0, W is a chemical bond, A is ethylene and R4 is hydrogen.
17. The compound of claim 16, wherein X is 6-methoxy, X1 is 7-methoxy, Q and Q1 are each hydrogen, p is 1, R is methoxy, m is 0, Y is 2-methoxy and Y1 is 3-methoxy.
18. The compound of claim 16, wherein X is 6-methoxy, X1 is 7-methoxy, Q and Q1 are each hydrogen, p is 2, R is hydrogen, m is 0, Y is 3-methoxy and Y1 is 4-methoxy.
19. The compound of claim 16, wherein X is 6-methoxy, X1 is 7-methoxy, Q is 7-amino, Q1 is hydrogen, R is hydrogen, m is 0, p is 1, Y is 3-methoxy and Y1 is 4-methoxy.
20. A compound of claim 1, wherein X and X1 are each alkoxy having one to four carbon atoms, X2 is hydrogen, R1 and R2 when taken together with the nitrogen atom to which they are attached form a moiety of the formula
Figure imgf000076_0001
wherein Q and Q1 are each alkoxy having one to three carbon atoms, Q2 is hydrogen, R and R5 are each hydrogen, p is 1, m is 0, R3 is aralkyl of the formula
Figure imgf000076_0002
wherein Q3 and Q4 are each alkoxy having one to three carbon atoms, R7 is methoxy, n is 1, A is methylene and R4 is hydrogen.
21. The compound of claim 20, wherein X is 6-methoxy, X1 is 7-methoxy, Q is 7-methoxy, Q1 is 8-methoxy, Q3 is 2-methoxy and Q4 is 4-methoxy.
22. A compound of claim 1, wherein X and X1 are each alkoxy having one to four carbon atoms, X2 is hydrogen, R1 and R2 when taken together with the nitrogen atom to which they are attached form a moiety of the formula
Figure imgf000076_0003
wherein Q1 and Q2 are each hydrogen, R5 is hydrogen, p is 1, m is 0, R3 is aralkyl of the formula
Figure imgf000077_0003
wherein Q3 and Q4 are each alkoxy having one to three carbon atoms, R7 is methoxy, n is 1, A is methylene and R4 is hydrogen.
23. The compound of claim 22, wherein X is 6-methoxy,
X1 is 7-methoxy, Q is 6-fluoro, R is methoxy, Q3 is 2-methoxy and Q4 is 3-methoxy.
24. A compound of claim 1, wherein X1 is alkoxy having one to four carbon atoms, X2 is hydrogen, R1 and R2 when taken together with the nitrogen atom to which they are attached form a moiety of the formula
Figure imgf000077_0001
wherein Q and Q1 are each alkoxy having one to three carbon atoms, Q2 is hydrogen, p is 1, m is 0, R3 is aralkyl of the formula
Figure imgf000077_0002
wherein Y2 is hydrogen, n is 0, W is a chemical bond, A is ethylene and R4 is hydrogen.
25. The compound of claim 24, wherein X is 6-chloro,
X1 is 7-methoxy, Q is 6-methoxy, Q1 is 7-methoxy, R and R5 are each hydrogen, Y is 3-methoxy and Y1 is 4-methoxy.
26. A method of inhibiting a P-glycoprotein in a mammal in need of such treatment which comprises adminis tering to said mammal a P-glycoprotein inhibiting amount of a compound according to claim 1.
27. A method of claim 26, wherein the mammal is a human suffering from cancer and said compound is administered before, with or after the administration to said human of an anticancer effective amount of a chemotherapeutic agent.
28. A pharmaceutical composition for administration to a mammal which comprises a P-glycoprotein inhibiting amount of a compound of claim 1, a pharmaceutically acceptable carrier and, optionally, an anticancer effective amount of a chemotherapeutic agent.
29. A process for preparing a compound of the formula
Figure imgf000078_0001
and a pharmaceutically acceptable acid addition salt thereof wherein X and X1 are each hydrogen, alkyl having one to four carbon atoms, alkoxy having one to four carbon atoms, bromo, nitro, iodo, methylsulfinyl, (CH3)2S⊕, amino, alkylamino having one to three carbon atoms, methylthio, aminomethyl, dialkylaminomethyl having three to seven carbon atoms, hydroxymethyl, morpholino, thiomorpholino, piperazino, benzoylamino, substituted benzoylamino wherein said substituent is azido, methoxy, methyl, fluoro, chloro or trifluoromethyl, alkanoylamino having two to four carbon atoms, 4-methylpiperizino, piperidino, pyrrolidino, dialkylamino having two to six carbon atoms, fluoro or chloro; X2 is hydrogen, alkyl having one to four carbon atoms or alkoxy having one to four carbon atoms; X and X1 together are ethylenedioxy or methylenedioxy; R1 is cycloalkyl having three to seven carbon atoms, alkoxyalkyl said alkoxy having one to three carbon atoms and said alkyl having two to three carbon atoms, alkyl having one to four carbon atoms or benzodioxan-2-ylmethyl; R2 is hydrogen, alkyl having one to eight carbon atoms or benzyl; R1 and R2 when taken together with the nitrogen atom to which they are attached form
(a) a moiety of the formula
Figure imgf000079_0001
wherein Q is hydrogen, alkoxy having one to three carbon atoms, hydroxy, alkanoylamino having two to four carbon atoms, alkyl having one to three carbon atoms, bromo, iodo, fluoro, chloro, nitro, amino, morpholino, alkylamino having one to three carbon atoms or dialkylamino having two to six carbon atoms, Q1 is hydrogen, fluoro, chloro, bromo, alkyl having one to three carbon atoms or alkoxy having one to three carbon atoms and Q2 is hydrogen or alkoxy having one to three carbon atoms, Q1 and Q2 together are ethylenedioxy or methylenedioxy, R is hydrogen, alkyl having one to four carbon atoms or alkoxy having one to three carbon atoms, m. is an integer of 0-2, p is an integer of 1-2, R5 is hydrogen or dialkoxybenzyl said alkoxy having one to three carbon atoms and R and R5 together are alkylene having one to three carbon atoms,
(b) 1,2,3,4-tetrahydro-beta-carbol-2-yl,
(c) piperidino of the formula
Figure imgf000079_0002
wherein R6 is pyridylmethoxy, alkoxyalkyleneoxy said alkoxy having from one to three carbon atoms and said alkylene having from two to three carbon atoms or benzoxazol-2- ylmethyl
(d) actahydroisoindol-2-yl or
(e) decahydroisoquinol-2-yl; R3 is
(a) cycloalkyl having three to seven carbon atoms,
(b) benzodioxan-2-ylmethyl,
(c) aralkyl of the formula
Figure imgf000080_0001
wherein n is an integer of 1 or 0, W is O, S or a chemical bond, A is alkylene having one to four carbon atoms, Y is hydrogen, alkyl having one to three carbon atoms, alkoxy having one to three carbon atoms, fluoro, chloro, bromo, hydroxy, benzyloxy, nitro, dimethylamino or amino, Y1 is hydrogen, alkoxy having one to three carbon atoms, chloro, fluoro, hydroxy or benzyloxy, Y2 is hydrogen or alkoxy having one to three carbon atoms and Y and Y1 together are ethylenedioxy or methylenedioxy,
(d) aralkyl of the formula
Figure imgf000080_0002
wherein R7 is hydroxy, alkoxy having one to three carbon atoms or C6H5(CH2)t-, n is 1, t is an integer of 0 or 1, A is alkylene having one to four carbon atoms, Q3 and Q4 are each hydrogen or alkoxy having one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy,
(e) pyridylalkyl said alkyl having from one to four carbon atoms,
(f) alkoxyalkyl said alkoxy having from one to three carbon atoms and said alkyl having two to three carbon atoms, (g) indolylalkyl of the formula
Figure imgf000081_0001
wherein A is alkylene having one to four carbon atoms, Q3 and Q4 are each hydrogen or alkoxy having one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy,
(h) tetrahydronaphthalene of the formula
Figure imgf000081_0002
wherein A is alkylene having one to four carbon atoms, Q3 and Q4 are each hydrogen or alkoxy having one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy,
(i) aralkanol of the formula
Figure imgf000081_0003
wherein W is O, S or a chemical bond and Q3 is hydrogen or alkoxy having one to three carbon atoms,
(j) 2,3-dihydro-2-hydroxyinden-1-yl,
(k) aracylcoalkyl of the formula
Figure imgf000081_0004
wherein A is alkylene having one to four carbon atoms, Q3 and Q4 are each hydrogen or alkoxy having one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy,
(1) indene of the formula
Figure imgf000082_0001
wherein Q3 and Q4 are each hydrogen or alkoxy having one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy,
(m) naphthyl or
(n) 1-methylpyrrol-2-yl;
R4 is hydrogen or alkyl having one to eight carbon atoms, and R3 and R4 when taken together with the nitrogen atom to which they are attached form
(a) a tetrahydro isoquinoline of the formula
Figure imgf000082_0002
wherein Q3 and Q4 are each hydrogen or alkoxy having one to three carbon atoms and Q3 and Q4 together are ethylenedioxy or methylenedioxy,
(b) piperidino of the formula
Figure imgf000082_0003
wherein R8 is benzyl, alkoxyalkyleneoxy said alkoxy having from one to three carbon atoms and said alkylene having two to three carbon atoms or alkyl sulfonamide of the formula
Figure imgf000083_0001
wherein R9 is alkyl having from one to four carbon atoms, (c) 3-methyl-3-phenylpiperidino or
(d) piperazino of the formula
Figure imgf000083_0003
wherein R10 is hydrogen, alkoxycarbonyl having from two to six carbon atoms, acyl having one to six carbon atoms, hydroxyalkoxy carbonyl having three to six carbon atoms, furoyl, benzoxazol-2-yl, pyrimid-2-yl or benzodioxan-2- carbonyl, which comprises reacting a compound of the formula
Figure imgf000083_0002
wherein R1, R2, X, X1 and X2 are defined with a compound of the formula
R3R4NH where R3 and R4 are defined in a reaction-inert solvent containing one equivalent of an amine-acid scavenger at a reaction temperature of 100-200ºC until the reaction is substantially complete.
PCT/US1991/007254 1990-11-06 1991-10-10 Quinazolines derivatives for enhancing antitumor activity WO1992007844A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CS924009A CZ400992A3 (en) 1990-11-06 1991-10-10 Quinazoline derivatives for enhancing anti-tumor activity
DE69111077T DE69111077T2 (en) 1990-11-06 1991-10-10 CHINAZOLE DERIVATIVES TO IMPROVE ANTITUARY EFFECT.
US08/050,047 US5444062A (en) 1990-11-06 1991-10-10 Quinazolines derivatives for enhancing antitumor activity
KR1019930701349A KR930702292A (en) 1990-11-06 1991-10-10 Quinazolin derivatives for enhancing tumor therapeutic activity
EP92900750A EP0556310B1 (en) 1990-11-06 1991-10-10 Quinazolines derivatives for enhancing antitumor activity
SK4009-92A SK400992A3 (en) 1990-11-06 1991-10-10 Quinazolines derivatives for enhancing antitumor activity
JP92501815A JPH05507290A (en) 1990-11-06 1991-10-10 Quinazoline derivatives for enhanced antitumor activity
BR9107070A BR9107070A (en) 1990-11-06 1991-10-10 Process for the preparation of quinazoline derivatives useful to improve antitumor activity.
FI932032A FI932032A0 (en) 1990-11-06 1993-05-05 KINAZOLINDERIVAT FOER OEKANDE AV ANTITUMOERAKTIVITET
NO931635A NO931635D0 (en) 1990-11-06 1993-05-05 PROCEDURE FOR THE PREPARATION OF CHINAZOLINE DERIVATIVES
GR950402241T GR3017122T3 (en) 1990-11-06 1995-08-16 Quinazolines derivatives for enhancing antitumor activity.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60998690A 1990-11-06 1990-11-06
US609,986 1990-11-06

Publications (1)

Publication Number Publication Date
WO1992007844A1 true WO1992007844A1 (en) 1992-05-14

Family

ID=24443149

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/007254 WO1992007844A1 (en) 1990-11-06 1991-10-10 Quinazolines derivatives for enhancing antitumor activity

Country Status (25)

Country Link
US (1) US5444062A (en)
EP (1) EP0556310B1 (en)
JP (1) JPH05507290A (en)
KR (1) KR930702292A (en)
CN (1) CN1061411A (en)
AT (1) ATE124694T1 (en)
BR (1) BR9107070A (en)
CA (1) CA2095213A1 (en)
CZ (1) CZ400992A3 (en)
DE (2) DE9190155U1 (en)
DK (1) DK0556310T3 (en)
ES (1) ES2074867T3 (en)
FI (1) FI932032A0 (en)
GR (1) GR3017122T3 (en)
HU (1) HUT64533A (en)
IE (1) IE913854A1 (en)
IL (1) IL99906A0 (en)
MX (1) MX9101913A (en)
NO (1) NO931635D0 (en)
NZ (1) NZ240476A (en)
PT (1) PT99415A (en)
SK (1) SK400992A3 (en)
WO (1) WO1992007844A1 (en)
YU (1) YU47993B (en)
ZA (1) ZA918767B (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010116A1 (en) * 1991-11-12 1993-05-27 Pfizer Inc. Triazine derivatives for enhancing antitumor activity
WO1994014795A1 (en) 1992-12-29 1994-07-07 Yuhan Corporation Quinazoline derivatives
EP0743308A2 (en) * 1995-05-16 1996-11-20 Kanebo, Ltd. Quinazoline compound and anti-tumor agent containing said compound as an active ingredient
WO1997020823A2 (en) * 1995-12-01 1997-06-12 Novartis Ag 2-amino quinazoline derivatives as npy receptor antagonists
WO1997020822A1 (en) * 1995-12-01 1997-06-12 Novartis Ag Quinazolin-2,4-diazirines as npy receptor antagonist
US5750531A (en) * 1994-08-13 1998-05-12 Yuhan Corporation Pyrimidine derivatives and processes for the preparation thereof
US6084095A (en) * 1994-01-25 2000-07-04 Warner-Lambert Company Substituted pyrido[3,2-d]pyrimidines capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
CN1058265C (en) * 1994-05-16 2000-11-08 株式会社柳韩洋行 Quinazoline derivatives
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
WO2002006288A1 (en) * 2000-07-18 2002-01-24 F.Hoffmann-La Roche Ag Tetrahydro-heterocycloazepinyl pyrimidine derivatives
US6352993B1 (en) 1997-03-27 2002-03-05 Yuhan Corporation Pyrimidine derivatives and processes for the preparation thereof
US6545008B1 (en) 1998-11-17 2003-04-08 Yuhan Corporation Pyrimidine derivatives and processes for the preparation thereof
WO2003051872A1 (en) * 2001-12-19 2003-06-26 Smithkline Beecham P.L.C. Ethylene diamine derivatives and their use as orexin-receptor antagonists
WO2003055866A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
US6596726B1 (en) 1994-01-25 2003-07-22 Warner Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
WO2004005265A1 (en) * 2002-07-05 2004-01-15 F. Hoffmann-La Roche Ag Quinazoline derivatives
WO2004092144A2 (en) * 2003-04-16 2004-10-28 F. Hoffmann-La Roche Ag Quinazoline compounds useful as p38 kinase inhibitors
WO2005033097A1 (en) * 2003-10-07 2005-04-14 Hanmi Pharm. Co., Ltd. P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same
US7022849B2 (en) 2001-06-19 2006-04-04 Bristol-Myers Squibb Co. Quinazoline and pyrido[2,3-d]pyrimidine inhibitors of phosphodiesterase (PDE) 7
WO2006108773A1 (en) * 2005-04-11 2006-10-19 F. Hoffmann-La Roche Ag (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines
WO2008006287A1 (en) 2006-07-05 2008-01-17 Tianjin Hemay Bio-Tech Co. Ltd Inreversible protein tyrosine kinases inhibitors and the preparation methods and uses thereof
US7544690B2 (en) 2001-10-01 2009-06-09 Taisho Pharmaceutical Co., Ltd. MCH receptor antagonists
WO2011113512A1 (en) 2010-03-16 2011-09-22 Merck Patent Gmbh Morpholinylquinazolines
DE102010025786A1 (en) 2010-07-01 2012-01-05 Merck Patent Gmbh Pyrazolochinoline
DE102010035744A1 (en) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
WO2013072015A1 (en) 2011-11-18 2013-05-23 Merck Patent Gmbh Morpholinyl benzotriazine for use in cancer therapy
DE102013008118A1 (en) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996016946A1 (en) * 1994-11-25 1996-06-06 Nippon Chemiphar Co., Ltd. Quinazoline derivative
EA001595B1 (en) * 1996-04-12 2001-06-25 Варнер-Ламберт Компани Irreversible inhibitors of tyrosine kinases.
DE60006618T2 (en) * 1999-08-06 2004-09-23 F. Hoffmann-La Roche Ag Tetrahydrobenzo (d) azepines and their use as metabotropic glutamate receptor antagonists
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
FR2845994B1 (en) * 2002-10-18 2006-05-19 Servier Lab NOVEL SUBSTITUTED BENZO [E] [1,4] OXAZINO [3,2-G] ISOINDOLE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US8673914B2 (en) 2011-03-28 2014-03-18 St. John's University Use of phosphodiesterase inhibitors for treating multidrug resistance
CN108014112B (en) * 2018-01-24 2020-10-09 浙江工业大学 Application of o-toluidine amino acetamido benzo [ d ] aza-based quinazoline compound in preparation of drugs for treating lung cancer
CN108129461B (en) * 2018-01-24 2020-08-21 浙江工业大学 Benzoylaminobenzo [ d ] aza-quinazoline compound, preparation and application thereof
CN108164510B (en) * 2018-01-24 2020-08-21 浙江工业大学 Chloroacetamidobenzo [ d ] aza-based quinazoline compound and preparation method and application thereof
CN108125961B (en) * 2018-01-24 2020-05-26 浙江工业大学 Application of morpholinyl acetamido methoxyphenyl benzazepinyl quinazoline compound in preparation of drugs for treating leukemia
CN108078994B (en) * 2018-01-24 2020-01-03 浙江工业大学 Application of 6- (2-morpholinyl acetamido) quinazoline compound in preparation of medicine for treating lung cancer
CN108276384B (en) * 2018-01-24 2019-12-06 浙江工业大学 acetaminobenzo [ d ] azepinyl quinazoline compound and preparation and application thereof
CN108276385B (en) * 2018-01-24 2019-12-06 浙江工业大学 Isobutyrylaminoquinazoline compounds, and preparation and application thereof
CN108309984B (en) * 2018-01-24 2020-02-21 浙江工业大学 Application of propionyl aminoquinazoline compound in preparation of medicine for treating cervical cancer
CN108186649B (en) * 2018-01-24 2020-05-26 浙江工业大学 Application of propionyl amino chloro benzo [ d ] aza-quinazoline in preparing medicament for treating leukemia
CN108329299B (en) * 2018-01-24 2020-08-21 浙江工业大学 Butyrylamino chloro benzo [ d ] aza-based quinazoline compound, preparation and application thereof
CN108143736B (en) * 2018-01-24 2020-08-21 浙江工业大学 Application of butyrylaminobenzo [ d ] aza-based quinazoline in preparation of drugs for treating lung cancer
CN108250185B (en) * 2018-01-24 2020-08-21 浙江工业大学 6- (2- (o-toluidine amino) acetamido) quinazoline compound, preparation and application thereof
CN108295076B (en) * 2018-01-24 2020-05-22 浙江工业大学 Application of propionyl-amino-dimethoxy-benzo [ d ] aza-quinazoline in preparation of drugs for treating lung cancer
CN108329300B (en) * 2018-01-24 2020-10-09 浙江工业大学 Nitrobenzo [ d ] aza-quinazoline compound and preparation method and application thereof
CN108033949B (en) * 2018-01-24 2019-11-29 浙江工业大学 6- (2- dipropyl aminoacetylamino) quinazoline compounds and preparation and application
CN108014116B (en) * 2018-01-24 2020-08-21 浙江工业大学 Application of aminodimethoxybenzo [ d ] aza-quinazoline compound in preparation of drugs for treating lung cancer
CN108129460B (en) * 2018-01-24 2020-10-09 浙江工业大学 Methoxyphenylbenzo [ d ] aza-quinazoline compound and preparation and application thereof
CN108125962B (en) * 2018-01-24 2020-08-21 浙江工业大学 Application of benzo [ d ] aza-quinazoline compound in preparation of drugs for treating lung cancer
CN108042546B (en) * 2018-01-24 2020-10-09 浙江工业大学 Application of morpholinyl acetamidobenzo [ d ] aza-based quinazoline compound in preparation of drugs for treating cervical cancer
CN108245521B (en) * 2018-01-24 2020-01-03 浙江工业大学 Application of dipropylaminoacetamidobenzazepinyl quinazoline compound in preparation of drugs for treating leukemia
CN108324718B (en) * 2018-01-24 2020-10-09 浙江工业大学 Application of cyclohexyl methoxy formyl amino chloro benzo aza group quinazoline compound in leukemia treatment drug
CN108125960B (en) * 2018-01-24 2020-08-21 浙江工业大学 Application of isobutyrylaminobenzo [ d ] aza-based quinazoline compound in preparation of drugs for treating lung cancer
CN108078993B (en) * 2018-01-24 2020-02-21 浙江工业大学 Application of 6-nitroquinazoline compound in preparation of medicine for treating lung cancer
CN109251196B (en) * 2018-01-24 2020-11-13 浙江工业大学 Aminobenzo [ d ] aza-quinazoline compound and preparation method and application thereof
CN108125959B (en) * 2018-01-24 2019-12-31 浙江工业大学 Application of dimethoxy phenylamino acetamido quinazoline compound in preparation of drugs for treating leukemia
CN108078992B (en) * 2018-01-24 2020-08-21 浙江工业大学 Application of pivaloyl-amino-dimethoxy-benzo [ d ] aza-quinazoline compound in preparation of drugs for treating leukemia
CN108245520B (en) * 2018-01-24 2019-12-24 浙江工业大学 Application of acetamido quinazoline compound in preparation of drugs for treating lung cancer
CN108017621B (en) * 2018-01-24 2020-08-21 浙江工业大学 Morpholinyl acetamido dimethoxy benzo [ d ] aza-based quinazoline compound and preparation and application thereof
CN108078995B (en) * 2018-01-24 2020-01-03 浙江工业大学 Application of benzoylaminoquinazoline compound in preparation of drugs for treating lung cancer
CN108276386B (en) * 2018-01-24 2020-10-09 浙江工业大学 Cyclohexyl methoxy formyl amino quinazoline compound and preparation and application thereof
CN108324717B (en) * 2018-01-24 2020-08-21 浙江工业大学 Application of pivaloylchlorobenzo [ d ] aza-quinazoline compound in preparation of drugs for treating cervical cancer
CN108324719B (en) * 2018-01-24 2020-08-21 浙江工业大学 Application of o-toluidino-acetamido-methoxy-phenyl benzazepinyl-quinazoline compound in preparation of cervical cancer treatment drug
CN108084162B (en) * 2018-01-24 2019-11-29 浙江工业大学 Dimethoxy benzene aminoacetylamino benzo [d] azepine * base quinazoline compounds and preparation and application
CN108117542B (en) * 2018-01-24 2019-12-24 浙江工业大学 Propionyl amino methoxyphenyl benzo [ d ] nitrogen hetero-pinyl quinazoline compound, preparation and application
CN108014114B (en) * 2018-01-24 2020-08-21 浙江工业大学 Application of chloroacetylamidoquinazoline compounds in preparation of drugs for treating lung cancer
CN108014113B (en) * 2018-01-24 2020-10-09 浙江工业大学 Application of butyrylamidodimethoxybenzo [ d ] aza-based quinazoline compound in preparation of drugs for treating cervical cancer
CN108125958B (en) * 2018-01-24 2020-08-21 浙江工业大学 Application of o-toluidine amino acetamido chloro benzazepine radical quinazoline compound in preparing medicament for treating leukemia
CN108014115B (en) * 2018-01-24 2020-10-02 浙江工业大学 Application of pivaloylaminomethoxyphenyl benzo [ d ] aza-quinazoline compound in preparation of lung cancer treatment drug
CN108047206B (en) * 2018-01-24 2019-11-29 浙江工业大学 Pivaloyl amino benzo [d] azepine * base quinazoline compounds and preparation and application
CN108245519B (en) * 2018-01-24 2020-02-21 浙江工业大学 Application of butyrylaminoquinazoline compound in preparation of drugs for treating leukemia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2389614A1 (en) * 1977-05-05 1978-12-01 Synthelabo Antihypertensive 2,4-di:amino-quinazoline(s) - prepd. from a 2-halo-4-amino-quinazoline and a secondary amine
EP0322133A1 (en) * 1987-12-03 1989-06-28 SmithKline Beecham Intercredit B.V. Quinazoline derivatives

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE958197C (en) * 1952-04-18 1957-02-14 Dr Siegfried Skraup Process for the preparation of 2,4-diaminochinazoline
CH457460A (en) * 1966-06-20 1968-06-15 Parke Davis & Co Process for the preparation of quinazolines
US3511836A (en) * 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
US3663706A (en) * 1969-09-29 1972-05-16 Pfizer Use of 2,4-diaminoquinazolines as hypotensive agents
GB1390015A (en) * 1971-05-07 1975-04-09 Koninklijke Pharma Fab Nv 4-amino-quinazoline compounds
GB1383409A (en) * 1972-09-09 1974-02-12 Pfizer Ltd Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them
US3956495A (en) * 1973-10-30 1976-05-11 Eli Lilly And Company 2,4-Diaminoquinazolines as antithrombotic agents
US4098788A (en) * 1977-06-20 1978-07-04 Bristol-Myers Company Process for preparing quinazolines
US4287341A (en) * 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
IL89027A (en) * 1988-01-29 1993-01-31 Lilly Co Eli Quinazoline derivatives, process for their preparation and fungicidal, insecticidal and miticidal compositions containing them
GB8910722D0 (en) * 1989-05-10 1989-06-28 Smithkline Beckman Intercredit Compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2389614A1 (en) * 1977-05-05 1978-12-01 Synthelabo Antihypertensive 2,4-di:amino-quinazoline(s) - prepd. from a 2-halo-4-amino-quinazoline and a secondary amine
EP0322133A1 (en) * 1987-12-03 1989-06-28 SmithKline Beecham Intercredit B.V. Quinazoline derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF MEDICINAL CHEMISTRY vol. 28, 1985, WASHINGTON pages 12 - 17; J. MILLEN ET AL.: '2-(beta-ARYLETHYLAMINO)- and 4-(beta-ARYLETHYLAMINO)QUINAZOLINES as PHOSPHODIESTERASE INHIBITORS' cited in the application SEE ON PAGE 12, PAGES 15 TO 17 *

Cited By (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5536722A (en) * 1991-11-12 1996-07-16 Pfizer Inc. Triazine derivatives for enhancing antitumor activity
WO1993010116A1 (en) * 1991-11-12 1993-05-27 Pfizer Inc. Triazine derivatives for enhancing antitumor activity
WO1994014795A1 (en) 1992-12-29 1994-07-07 Yuhan Corporation Quinazoline derivatives
US5686458A (en) * 1992-12-29 1997-11-11 Yuhan Corporation Quinazoline deriviates for treating peptic ulcer
US6521620B1 (en) 1994-01-25 2003-02-18 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US6455534B2 (en) 1994-01-25 2002-09-24 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US6596726B1 (en) 1994-01-25 2003-07-22 Warner Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US6713484B2 (en) 1994-01-25 2004-03-30 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US6265410B1 (en) 1994-01-25 2001-07-24 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US6084095A (en) * 1994-01-25 2000-07-04 Warner-Lambert Company Substituted pyrido[3,2-d]pyrimidines capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
CN1058265C (en) * 1994-05-16 2000-11-08 株式会社柳韩洋行 Quinazoline derivatives
US5750531A (en) * 1994-08-13 1998-05-12 Yuhan Corporation Pyrimidine derivatives and processes for the preparation thereof
EP0743308A2 (en) * 1995-05-16 1996-11-20 Kanebo, Ltd. Quinazoline compound and anti-tumor agent containing said compound as an active ingredient
EP0743308A3 (en) * 1995-05-16 2000-04-05 Kanebo, Ltd. Quinazoline compound and anti-tumor agent containing said compound as an active ingredient
WO1997020822A1 (en) * 1995-12-01 1997-06-12 Novartis Ag Quinazolin-2,4-diazirines as npy receptor antagonist
WO1997020823A3 (en) * 1995-12-01 1997-07-17 Ciba Geigy Ag 2-amino quinazoline derivatives as npy receptor antagonists
WO1997020823A2 (en) * 1995-12-01 1997-06-12 Novartis Ag 2-amino quinazoline derivatives as npy receptor antagonists
US6352993B1 (en) 1997-03-27 2002-03-05 Yuhan Corporation Pyrimidine derivatives and processes for the preparation thereof
US6277989B1 (en) 1998-08-28 2001-08-21 Scios, Inc. Quinazoline derivatives as medicaments
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US6903096B2 (en) 1998-08-28 2005-06-07 Scios, Inc. Quinazoline derivatives as medicaments
US6545008B1 (en) 1998-11-17 2003-04-08 Yuhan Corporation Pyrimidine derivatives and processes for the preparation thereof
WO2002006288A1 (en) * 2000-07-18 2002-01-24 F.Hoffmann-La Roche Ag Tetrahydro-heterocycloazepinyl pyrimidine derivatives
US7022849B2 (en) 2001-06-19 2006-04-04 Bristol-Myers Squibb Co. Quinazoline and pyrido[2,3-d]pyrimidine inhibitors of phosphodiesterase (PDE) 7
US7601836B2 (en) 2001-06-19 2009-10-13 Bristol-Myers Squibb Company Pyrido[2,3-D]pyrimidine inhibitors of phosphodiesterase (PDE) 7
US7544690B2 (en) 2001-10-01 2009-06-09 Taisho Pharmaceutical Co., Ltd. MCH receptor antagonists
WO2003051872A1 (en) * 2001-12-19 2003-06-26 Smithkline Beecham P.L.C. Ethylene diamine derivatives and their use as orexin-receptor antagonists
US7468367B2 (en) 2001-12-19 2008-12-23 Smithkline Beecham P.L.C. Ethylene diamine derivatives and their use as orexin-receptor antagonists
WO2003055866A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
WO2004005265A1 (en) * 2002-07-05 2004-01-15 F. Hoffmann-La Roche Ag Quinazoline derivatives
US7205309B2 (en) 2002-07-05 2007-04-17 Hoffmann-La Roche Inc. Quinazoline derivatives
US7456185B2 (en) 2003-04-16 2008-11-25 Roche Palo Alto Llc Substituted quinazoline compounds useful as p38 kinase inhibitors
WO2004092144A2 (en) * 2003-04-16 2004-10-28 F. Hoffmann-La Roche Ag Quinazoline compounds useful as p38 kinase inhibitors
WO2004092144A3 (en) * 2003-04-16 2005-03-24 Hoffmann La Roche Quinazoline compounds useful as p38 kinase inhibitors
US7238698B2 (en) 2003-04-16 2007-07-03 Roche Palo Alto Llc Substituted quinazoline compounds useful as p38 kinase inhibitors
WO2005033097A1 (en) * 2003-10-07 2005-04-14 Hanmi Pharm. Co., Ltd. P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same
US7625926B2 (en) 2003-10-07 2009-12-01 Hanmi Pharm. Co., Ltd P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same
KR100938297B1 (en) * 2005-04-11 2010-01-22 에프. 호프만-라 로슈 아게 3,4-dihydro-quinazolin-2-yl-indan-1-yl-amines
US7348332B2 (en) 2005-04-11 2008-03-25 Hoffmann-La Rochse Inc. (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines
WO2006108773A1 (en) * 2005-04-11 2006-10-19 F. Hoffmann-La Roche Ag (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines
WO2008006287A1 (en) 2006-07-05 2008-01-17 Tianjin Hemay Bio-Tech Co. Ltd Inreversible protein tyrosine kinases inhibitors and the preparation methods and uses thereof
WO2011113512A1 (en) 2010-03-16 2011-09-22 Merck Patent Gmbh Morpholinylquinazolines
US9126952B2 (en) 2010-03-16 2015-09-08 Merck Patent Gmbh Morpholinylquinazolines
US8802712B2 (en) 2010-07-01 2014-08-12 Merck Patent Gmbh Pyrazoloquinolines
WO2012000632A1 (en) 2010-07-01 2012-01-05 Merck Patent Gmbh Pyrazolo-quinolines
DE102010025786A1 (en) 2010-07-01 2012-01-05 Merck Patent Gmbh Pyrazolochinoline
US9000153B2 (en) 2010-08-28 2015-04-07 Merck Patent Gmbh Imidazo[4,5-c]quinolines as DNA-PK inhibitors
WO2012028233A1 (en) 2010-08-28 2012-03-08 Merck Patent Gmbh Imidazo[4,5-c]quinolines as dna-pk inhibitors
US9598408B2 (en) 2010-08-28 2017-03-21 Merck Patent Gesellschaft Mit Beschrankter Haftung Imidazo[4,5-C]quinolines as DNA-PK inhibitors
DE102010035744A1 (en) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
US9187469B2 (en) 2011-11-18 2015-11-17 Merck Patent Gmbh Morpholinylbenzotriazines for use in cancer therapy
DE102011118830A1 (en) 2011-11-18 2013-05-23 Merck Patent Gmbh Morpholinylbenzotriazine
WO2013072015A1 (en) 2011-11-18 2013-05-23 Merck Patent Gmbh Morpholinyl benzotriazine for use in cancer therapy
WO2014183850A1 (en) 2013-05-11 2014-11-20 Merck Patent Gmbh Arylquinazolines
DE102013008118A1 (en) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
US9732094B2 (en) 2013-05-11 2017-08-15 Merck Patent Gmbh Arylquinazolines
US10172859B2 (en) 2013-05-11 2019-01-08 Merck Patent Gmbh Arylquinazolines
US10383874B2 (en) 2013-05-11 2019-08-20 Merk Patent Gmbh Arylquinazolines
US11065253B2 (en) 2013-05-11 2021-07-20 Merck Patent Gmbh Arylquinazolines

Also Published As

Publication number Publication date
PT99415A (en) 1992-09-30
IE913854A1 (en) 1992-05-22
DE9190155U1 (en) 1993-10-07
YU176191A (en) 1994-01-20
EP0556310A1 (en) 1993-08-25
ES2074867T3 (en) 1995-09-16
MX9101913A (en) 1992-07-08
HU9301314D0 (en) 1993-09-28
CA2095213A1 (en) 1992-05-07
FI932032A (en) 1993-05-05
DE69111077T2 (en) 1995-11-02
CZ400992A3 (en) 1993-12-15
ATE124694T1 (en) 1995-07-15
AU9059291A (en) 1992-05-26
EP0556310B1 (en) 1995-07-05
IL99906A0 (en) 1992-08-18
YU47993B (en) 1996-08-13
HUT64533A (en) 1994-01-28
SK400992A3 (en) 1995-08-09
US5444062A (en) 1995-08-22
JPH05507290A (en) 1993-10-21
NZ240476A (en) 1994-04-27
BR9107070A (en) 1994-05-31
KR930702292A (en) 1993-09-08
DE69111077D1 (en) 1995-08-10
NO931635L (en) 1993-05-05
ZA918767B (en) 1993-05-05
FI932032A0 (en) 1993-05-05
GR3017122T3 (en) 1995-11-30
NO931635D0 (en) 1993-05-05
DK0556310T3 (en) 1995-08-21
AU644035B2 (en) 1993-12-02
CN1061411A (en) 1992-05-27

Similar Documents

Publication Publication Date Title
EP0556310B1 (en) Quinazolines derivatives for enhancing antitumor activity
EP0572437B1 (en) 2,4-diaminoquinazolines derivatives for enhancing antitumor activity
KR102630069B1 (en) Apoptosis-inducing agent
US8314085B2 (en) Agent for overcoming resistance to anti-cancer agent
EP0580753B1 (en) Pyrimidine derivatives for enhancing antitumor activity
WO1993017021A1 (en) Heterocyclic compounds for enhancing antitumor activity
EP0339976B1 (en) Anti-tumour agents
AU644035C (en) Quinazolines derivatives for enhancing antitumor activity
US5491234A (en) Pyrimidine derivatives for enhancing antitumor activity
KR20200035029A (en) Heterochromatin gene inhibition inhibitor
KR100566194B1 (en) Novel 3-nitropyridine derivatives and pharmaceutical compositions thereof
RU2782469C2 (en) Apoptosis-inducing agents
CN117384124A (en) HDAC inhibitors, compositions and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CS DE FI HU JP KR NO PL SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: PV1992-4009

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2095213

Country of ref document: CA

Ref document number: 1992900750

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 932032

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1992900750

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1992-4009

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1992900750

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: PV1992-4009

Country of ref document: CZ